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1. PURPOSE AND PLAN OF WORK
1.1 PURPOSE OF WORK
The purpose of the study is to develop Press coated tablets (PCT) 
of Propranolol Hcl for Chronotherapeutic delivery. Propranolol Hcl is used 
in the treatment of hypertension, arrhythmia, angina pectoris. According to 
circadian rhythm  (24hr- Biological clock) the Blood pressure (BP) will be 
more in early morning 3a.m – 6a.m because renin, cortisol, angiotensin, 
aldosterone  secretion  is  in  peak  level,  most  of  the  cardio  vascular 
disorders such as Angina pectoris, sudden cardiac death, stroke, occurs in 
this time, the designed formulation to be  taken at bed time and the focus 
is to optimally deliver the drug in higher amounts in early morning hours 
(i.e. at time of greatest need) and lower amounts at night (i.e. when the 
need of drug is less).
Propranolol  is  a  highly  lipophilic  drug  and  is  almost  completely 
absorbed  after  oral  administration.  However,  its  bioavailability  is  very 
limited (30%) due to the hepatic first-pass effect. Its elimination half-life is 
also relatively short (about 2–6 h). Therefore, it was chosen as a model 
drug for preparation of the once-daily controlled onset extended release 
(COER) dosage form.
 An  oral  time  controlled  release  formulation  facilitates  the 
administration,  just  once a  day to  control  the  BP in  patient  with 
morning surge, which results in better compliance by patients and 
fewer side effects.
 The main aim of the work is to achieve time-controlled release with 
distinct predetermined lag time.
 To study the effect  of  formulation of  outer  shell  comprising both 
hydrophobic  polymer  and  hydrophilic  swellable  polymers  on  the 
time lag of drug release.
 To find out the suitable weight ratios of polymers, to modulate the 
lag time.
 To  study  the  drug  release  kinetics  from data  obtained  through  
in vitro dissolution studies.
1.2 PLAN OF WORK
The present work was carried out in the following phases.
Phase 1 : Literature survey on chronotherapeutic delivery of 
propranolol  Hcl  drug  and  time  controlled  release 
dosage forms.
Phase 2 : Preformulation studies
Phase 3 : Formulation of time-controlled release press-coated 
tablets  of  propranolol  Hcl  using  hydrophilic  
swellable excipients and hydrophobic polymers.
Phase 4 : Evaluation studies
Phase 5 : Drug release kinetics.
2.  INTRODUCTION
2.1  Chronotherapeutic drug delivery system1   
Chronotherapeutics  is  the  delivery  of  medications  in  the  right 
concentration  to  the  right  targeted  tissues  at  the  right  time  to  meet 
biological rhythm-determined needs, e.g., rhythms in the mechanisms of 
disease,  symptom  intensity,  and/or  patient  tolerance,  to  optimize 
therapeutic outcomes and minimize adverse effects.
 “Chronopharmaceutics” consists  of  two  words  chronobiology 
and pharmaceutics. Chronobiology is the study of biological rhythms and 
their mechanisms.
A biologic rhythm is a self-sustaining oscillation. It is defined by its 
period,  amplitude,  and  phasing.  There  are  three  types  of  biological 
rhythms in our body, they are:
i. Circadian rhythm
ii. Ultradian rhythm
iii. Infradian rhythm
Circadian rhythm:  This word comes from latin word 
 “circa” means about
 “dies” means day. 
A rhythm with a period close or equal to 24 h is termed as circadian.
Ultradian rhythm:
Oscillation of shorter duration are termed as ultradian (more than 
one cycle per 24 h). Eg:  High-frequency oscillations in electrical impulses 
of the brain and heart, and the pulsatile secretion of hormones.
Infradian rhythm:
Oscillations that are longer than 24 h (less than one cycle per day)
Example: Menstrual and seasonal oscillations
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                          Table 1 :  Spectrum of biologic rhythms1
Category of
rhythms
Period of
rhythms
Term used to
describe 
rhythm
Illustrative examples
Short 
periods ≤ Sec
High  frequency 
Oscillations
Electroencephalogram
Electrocardiogram
Medium 
periods
30 min to 20 h
20 h to 28 h
Ultradian
Circadian
Sleep staging
Pulsatile  hormone 
secretion
Most biologic functions
Long periods
28 h to 6 days
~week
~Month
~Year
Infradian
Circaseptan
Circamensual
Circannual
Little studied thus far
Work–rest routine
Menstruation, fertility
Neuroendocrine 
functions.
Many  biochemical, 
endocrine, and
Physiological 
parameters.
2.2   The circadian time structure2
The results of numerous biologic rhythm studies help to define the 
temporal  organization  of  human  beings.  One  means  of  illustrating  the 
human circadian time structure is to depict the peak time of 24-h rhythms 
on a clock-like diagram shown in Fig. 1 
 The peak in  basal  gastric  acid  secretion,  white  blood  cell  count 
(WBC),  and  calcitonin  gene–related  protein  and  atrial  natriuretic 
peptides (both exerting BP–lowering effects) is late at night or early 
in sleep.
 Growth and thyroid stimulating hormone (TSH), blood lymphocyte 
and eosinophil number, and plasma concentration of melatonin and 
prolactin crest later in sleep, 
 As  do  adrenocorticotropic  hormone  (ACTH),  follicle  stimulating 
hormone  (FSH),  and  luteinizing  (LH)  hormone.  Plasma  cortisol, 
renin activity,angiotensin, and aldosterone crest in the morning as 
do  arterial  compliance,  vascular  resistance,  platelet  aggregation, 
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and blood viscosity.
 Hemoglobin  and  insulin  are  greatest  in  the  afternoon.  Serum 
cholesterol and triglycerides and urinary diuresis are highest early 
in the evening. 
The  information  conveyed  in  this  and  other  such  figures  clearly 
shows the biochemistry and physiology of human beings are not constant; 
rather, they are variable in a predictable manner during the 24-h period.
Fig.1 Biological clock shows circadian time structure of peak 
secretions and changes in our body.
ACTH = adrenocorticotropic hormone; FSH = follicle stimulating hormone;
LH = luteinizing hormone; TSH = thyroid stimulating hormone; 
WBC = white blood cells. 
2.2.1   Diagnostic tests: Circadian rhythm dependencies1
Several diagnostic tests are affected by circadian rhythms shown in 
Table 2.
Table 2 : Circadian rhythms: impact on the diagnosis of 
5
medical conditions
Allergy: Cutaneous  reaction  to  intradermal  antigen  tests  two-  to 
threefold greater in evening than in morning.
COPD: Airway patency best  in  the  afternoon and poorest  overnight. 
Morning  best  time  to  assess  severity  of  asthma  and  differentiate 
between fixed and reversible airway disease.
Glaucoma:  Intraocular  pressure  highest  during  sleep  and  lowest  in 
afternoon. Early morning eye exams best for assessing at-risk patients; 
false-negative diagnosis more of a risk in the afternoon.
Circadian  rhythm  sleep  disorders:  Sleep  phase  delay  syndrome 
(abnormally  retarded  sleep  onset  and  offset  times),  sleep  phase 
advanced  syndrome  (abnormally  advanced  sleep  onset  and  offset 
times) and non–24-h sleep–wake syndrome (period of the sleep–wake 
cycle  considerably  different  from  24  h)  best  diagnosed  by  wrist 
actigraphy.
Diabetes:  Results  of  glucose  tolerance test  different  in  the  morning 
than in afternoon, different times of the menstrual cycle, and different 
seasons of the year.
Laboratory chemistries: Plasma cortisol, melatonin, testosterone, and 
certain other hormone concentrations differ radically over the 24 h as do 
certain other commonly assessed blood constituents and parameters in 
hematology,  such  as  the  number  of  circulating  granulocytes, 
lymphocytes, and their subtypes.
Blood  pressure  assessment:  SBP  and  DBP  rapidly  rise  in  the 
morning by at least 15 to 25 mm Hg and reach highest levels late in the 
day.  Typically  SBP and DBP decline  in  sleep by 10% to  20% from 
daytime level.  In uncomplicated essential  hypertension, the pattern is 
similar, but the BP amplitude and/or 24-h mean abnormally elevated. In 
secondary hypertension, SBP and DBP may be normal or near normal 
in the day but abnormally high in sleep.
BP  =  blood  pressure;  COPD  =  chronic  obstructive  pulmonary  
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disease;  DBP = diastolic  blood pressure;  SBP =  systolic  blood  
pressure.
2.2.2   Circadian rhythms of disease3
The symptom intensity of most medical conditions, including ones 
that involve the cardiovascular system, and occurrence of life-threatening 
medical emergencies exhibit rather precise timings (Fig. 2).
 Gout,  gallbladder,  and peptic ulcer attacks are most frequent at  
night.
 Acute  pulmonary  edema,  congestive  heart  failure  and  asthma  
worsen nocturnally. 
 Sudden infant death syndrome occurs most frequently in the middle 
of the night.
 Symptoms  of  allergic  rhinitis  and  rheumatoid  arthritis  are  most  
intense in the morning.
 Migraine headache typically is triggered during rapid eye movement 
(REM) episodes toward the end of nighttime sleep or early in the 
morning.
 Angina pectoris, acute myocardial infarction, sudden cardiac death, 
ventricular  arrhythmia,  stroke,  fatal  pulmonary  embolism,  and 
hypertensive crises are most frequent in the morning, as are certain 
other cardiovascular conditions. 
 Depression is most severe in the morning. 
 Symptoms  of  osteoarthritis  worsen  during  the  course  of  daily  
activity, usually being most bothersome in the evening. 
 Perforated and bleeding ulcer is most common in the afternoon.   
 Some  seizure  disorders  are  triggered  in  specific  sleep  stages  
and/or by transitions between sleep and wakefulness.
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Fig. 2. Times when common medical conditions are likely to worsen 
and when morbid and mortal events are likely to occur with reference 
to the diurnal activity–nocturnal sleep routine of patients4.
2.3   Circadian BP pattern1
The cardiovascular system, including blood pressure (BP) and heart 
rate (HR),are characterized by predictable changes during the 24 h, for the 
most part,  in synchrony with the rest–activity cycle.  The internal factors 
which influences the circadian BP are,
 Ethnicity,
 Gender,
 Autonomic nervous system tone, 
 Vasoactive hormones, 
 Hematologic variable, and Renal variable.
 BP is also affected by a variety of external factors, including 
 Ambient temperature/humidity,
 Physical activity, 
 Emotional state, 
 Alcohol/caffeine consumption,
 Meal composition, and Sleep/wake routine. 
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           During the past two decades specific features of the 24-hour BP 
pattern have been assessed as potential sources of injury to target tissues 
and  as  triggers  of  cardiac  and  cerebrovascular  events  in  hypertensive 
patients. Indeed, the prominent 24-hour variation in the occurrence of a 
variety of acute cardiovascular events, such as 
             Myocardial infarction, angina pectoris, cardiac arrest, sudden 
cardiac death, and pulmonary embolism, have been shown to be closely 
related to the circadian BP pattern of hypertensive subjects. 
             Indeed, the rate of rise of BP coincident with the commencement 
of diurnal activity has been identified as an independent predictor of one's 
risk  of  morning  stroke  and  acute  coronary  syndrome,  and  it  is  also 
hypothesized to be a trigger for myocardial infarction at this time of day. 
Interestingly,  some studies reveal the 24-hour pattern and, in particular, 
the characteristic morning peak in the occurrence of both ischemic and 
hemorrhagic stroke  is  the  same  in  normotensive  and  hypertensive 
persons. 
Collectively,  all  these observations strengthen the hypothesis that 
the  morning  surge  in  BP  (in  the  presence  or  absence  of  systemic 
hypertension) is a crucial determinant of the rupture of a vulnerable and 
critically weakened arterial wall.
Fig.3. Circadian rhythm of systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) in hypertensive persons
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Circadian  rhythm  of  systolic  blood  pressure  (SBP)  and  diastolic 
blood pressure (DBP) in stage I essential hypertensive persons assessed 
by  24-h  ambulatory  blood  pressure  monitoring.  Time along  the  X  axis 
designates  hours  before  and  after  waking  from  sleep.  Note  the  rapid 
acceleration of BP at the commencement of the daily activity span.
              A growing number of studies also indicate the extent of the  
nocturnal BP decline is deterministic of cardiovascular injury and risk. The 
recent VIIth report of the Joint National Committee states that
“Those individuals in whom a 10 to 20% decrease of BP during 
early  morning  is  not  present  are  at  increased  risk  for  cardiovascular 
events”.  The  chronotherapy  of  hypertension  takes  into  account  the 
epidemiology of the circadian BP pattern, Specifically, it entails significant 
attenuation of the accelerated morning rise of systolic (SBP) and diastolic 
(DBP) BP, normalization of elevated daytime, nighttime, and 24-hour BP 
means,  and  conversion  of  an  abnormal  24-hour  BP  profile,  which  is 
associated with reduced cardiovascular risk.
Chronotherapy antihypertensive medications. The pharmacotherapy 
of  hypertension  has  been  strongly  influenced  by  the  concept  and 
assumptions of homeostasis. Until the last 10 or so years, the vast majority 
of the medical community believed SBP and DBP to be relatively constant 
throughout the 24 h. Consequently,  it  was deduced that a major goal  of 
antihypertensive  pharmacotherapy  ought  to  be  constancy  of  medication 
blood and tissue concentrations throughout the 24-hour dosing interval. 
The chronotherapeutic perspective of 24-hour BP control entails the 
purposeful tailoring of medication level in close synchrony with the known 
(and  expected)  day–night  pattern  in  SBP and  DBP to  optimize  effect.  
Chronotherapeutic formulations rely on unique technologies to distribute 
this proportion of the daily dose to the time of day when BP rises to peak 
or  near  peak  levels  and  when  the  greatest  concentration  of 
antihypertensive medications is required for BP control. 
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2.4   Biologic rhythms and medications3
Chronopharmacology  the study of how biologic rhythms affect 
medications,  has  led  to  new  understandings  and  concepts  about  the 
behavior of therapeutic agents.
Chronopathology  is  the  study  of  biological  rhythms  in  disease 
processes and in morbid and mortal events. Most medical conditions are 
affected by circadian rhythms. Cardiovascular diseases, which account for 
the greatest morbidity and mortality, are greatly affected by body rhythms. 
It is now generally recognized that myocardial infarctions, sudden cardiac 
death, transient ischemic attacks, and cerebrovascular accidents occur at 
a  higher  frequency  in  the  early  morning  hours.  In  this  issue,  new 
information is provided in this evolving area of research.
              
            Fig.4: Flowchart depicting a transition in therapeutics3
Chronokinetics : Refers to biologic rhythm effects on drug absorption, 
distribution,  and elimination.  Circadian changes in  gastric  hydrogen ion 
secretion,  stomach  emptying/  gastrointestinal  transit  time,  liver  enzyme 
activity,  and  organ  blood  flow,  for  example,  can  cause  treatment  time 
differences  in  the  pharmacokinetics  of  medications.  Chronokinetic 
phenomena may be specific to the chemical nature of the medication itself 
or to the physiochemical attributes of tablet, capsule, and aerosol drug-
delivery technology. β-adrenergic receptor antagonists, theophylline, and 
nonsteroidal anti-inflammatory drugs (NSAID) are but a few examples of 
prescribed medications that show administration time (circadian rhythm) 
dependent differences in kinetics.
Chronesthesy:  is another new concept in pharmacology. It refers 
to rhythm-dependent differences in the effects of medications that cannot 
be  explained  by  their  pharmacokinetics.  Chronesthesies  result  from 
Dose Chronotherapeutic  Antihypertensive Drugs Once Daily
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rhythms  in  drugfree-  fraction  and  rhythms  in  receptor  number  and 
conformation,  second  messenger  dynamics,  and  rate-limiting  steps  of 
metabolic pathways in drug-targeted tissues.
Analgesics,  anticoagulants,  β-adrenergic  receptor  agonists  and 
antagonists, corticosteroids, and NSAID are some examples of therapies 
that differ in effect according to their biologic time of administration.
 Chronotoxicity:  Refers specifically to rhythm-dependencies in the 
manifestation and intensity of drug-related side effects. Medications that 
have a narrow therapeutic window and high risk of adverse effects (eg, 
NSAID, synthetic corticosteroids, and antitumor agents) commonly display 
significant circadian chronotoxicities.
Chronotherapeutics  can  also  involve  the  application  of  physical 
agents. The successful management of certain conditions such as non–
24-h sleep–wake disorder, seasonal affective disorder, and premenstrual 
dysphoric  disorder,  can be achieved  by bright-light  chronotherapy.  The 
efficiency  of  radiotherapy  for  solid  tumors  is  best  when  it  is  timed  to 
coincide with  the peak in tumor metabolism during the 24 h.  The best 
known and most extensively used chronotherapy is the daily and alternate-
day morning dosing schedule of corticosteroid medications. The principal 
goal of this treatment schedule is to ensure that the highest concentration 
of  the  synthetic  hormone  coincides  in  time  with  the  morning  peak  of 
cortisol.  In  diurnally  active  individuals,  this  is  when  the  hypothalamic-
pituitary-adrenocortical  axis  is  least  vulnerable  to  suppression  by 
exogenous corticosteroids. A list of other chronotherapies that are now in 
use in clinical medicine is presented in Table 3.
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Table 3.  Chronotherapies currently in clinical use1
• Once-daily  and  alternate-day  morning  corticosteroids  dosing  
minimizes risk of adrenal suppression and other side effects.
• Bedtime  corticosteroid  dosing  controls  excessive  hormone  
secretion in congenital adrenal hyperplasia.
• Asymmetrical  morning  high  and  late-afternoon  low-dose  
corticosteroid substitution chronotherapy for Addison’s disease best 
corrects fatigue and abnormal circadian time structure.
• Evening  ingestion  of  certain  HMG-CoA  reductase  antagonist  
medications optimizes cholesterol-lowering effect.
• Nitroglycerin transdermal patch medication worn during the portion 
of  the  24 h to  protect  against  angina when  risk  is  greatest  and 
removed in time to avoid sensitization to medication.
• Evening H2-receptor antagonist ingestion best controls nocturnal  
peptic ulcer and gastroesophageal reflux disease(GERD).
• Evening  NSAID  treatment  optimizes  attenuation  of  morning 
symptoms of rheumatoid arthritis; midday and/or afternoon NSAID 
treatment best for osteoarthritis that is typically worse in evening.
• Bedtime  ADH  analogue  dosing  helps  to  alleviate  nocturnal  
bedwetting in children and nocturia in adults.
• Bedtime  (but  not  morning)  aspirin  dosing  best  for  preventing  
pregnancy-induced hypertension and preeclampsia.
• Evening theophylline chronotherapy (Uniphyl),  producing highest  
drug concentration in sleep, optimizes control of nocturnal asthma 
and COPD.
• Evening verapamil  chronotherapy (Verelan  PM and Covera-HS)  
achieves  more  complete  24-h  BP  control  than  once-a-day  
conventional constant-release medications.
• Timed melatonin and bright-light chronotherapies enhance speed of 
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adjustment  to  alteration  of  the  sleep–wake  routine  after  rapid 
transmeridian displacement by airplane or rotation between day and
night shifts.
• Timed bright-light chronotherapy is effective for seasonal affective 
disorder  (SAD),  premenstrual  dysphoric  disorder  (PMDD),  and 
circadian  rhythm  sleep  disorders  (advanced  and  delayed  sleep 
phase syndromes and non–24-h sleep–wake cycle disorder).
• Luteal phase (commencing 6 to 14 days before menses) therapy of 
premenstrual  dysphoric  disorder  (PMDD)  using  alprazolam, 
clomipramine, citalopram, fluoxetine, or sertraline.
• Infusion of cancer medications in synchrony with circadian rhythms 
minimizes  drug-induced  toxicity,  enabling  more  aggressive  
treatment. 
HMG-CoA =3-hydroxy-3methylglutaryl-coenzyme A; H2 = histamine 
type-2; NSAID = nonsteroidal  anti-inflammatory drug; ADH =Antidiuretic 
hormone; COPD = chronic obstructive pulmonary disease.
           Therapy with modified release dosage forms with zero order drug 
release  theoretically  leads  to  controlled  and  constant  levels  of  drug  in 
plasma  throughout  the  day.  However  this  does  not  provide  extra 
therapeutic  levels  at  the  time  of  increased  symptoms,  and  unwanted 
plasma drug concentration at  other  times of  day may produce adverse 
effects with little therapeutic benefit. In order to optimize therapy in terms 
of  safety,  patient  compliance  and  efficacy,  chronopharmaceutical 
formulations based upon time controlled drug delivery systems (TCDDS) 
are considered to be potential  therapeutic  options.  TCDDS are dosage 
forms that are designed to mimic the circadian rhythm of the disease by 
releasing the drug at the appropriate time.
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2.5   Compression coated (or) Press coated tablets6
Tablet is defined as unit dose solid dosage form containing one or 
more drug with or without excipients having a definite pharmacological 
action.
The compressed tablets are made by more than one compression 
cycle. Recently a compression coated tablet has received increasing 
attention to deliver a drug in a pulsatile fashion rather than in a continuous 
way at predetermined times and/ or sites following oral administration.
          This novel system not only rate controlled but time controlled to 
deliver the drug when it is required.
           The compression coated tablet consists of an inner core and an 
outer coating shell. The outer coating material may be compressed on to 
the inner core with a special compression technique.
           The manufacturing method of this tablet cannot only eliminate the 
time consuming and complicated operation processes but also improves 
the stability of drug by preventing it from moisture. To design a novel 
compression-coated tablet, the outer coating layer is critical in ensuring 
reliable tolerance to reach the predetermined site.
          These are also referred to as dry-coated are prepared by feeding 
previously compressed tablet into a special tabletting machine and 
compressed another granulation layer around the preformed tablets.
2.5.1 Production of tablets
           Tablets are made by compressing the formulation containing a drug 
or drugs with excipients on stamping machines called presses. Tablet 
compression machine or tablet presses are designed with the following 
basic components.
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1. Hoppers for holding and feeding granulation to be compressed
2. Dies that define the size and shape of the tablet.
3. Punches for compressing the granulation within the dies.
4. Camtracks for guiding the movement of the punches.
5. A feeding mechanism for moving granulation from the hopper into 
the dies.
    An example of a press-coated tabletting machine is the manesty 
drycota. Drycota : In 1937 killion , a german inventor received a british 
patent for a unit which compressed tablets on one machine and held them 
in the upper punches. These punches had rods passing lengthwise 
through them. The compression wheel was recessed so that it could 
compress the cores without activating the core rod. The cores were carried 
around the turret to the transfer mechanism. At this point the upper 
punches passed under a roller which pressed down the core rods, to the 
coating machine. It is evident that the drycota adopted the idea of two 
machines running synchronously from this patent.
2.5.2   Advantages of press coated tablets: 
1. They have all the advantages of compressed tablets i.e. slotting, 
monogramming, speed of disintegration.
2. Masking the taste of the drug substance in the core tablets.
3. Used to separate incompatible drug substances.
4. Means of giving an enteric coating to the core tablets
5. Widely used in prolonged dosage forms.
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2.6  Ideal characteristics of tablet dosage form5
 It has its own identity free of chips, cracks, discoloration and 
contamination.
 Should have strength to withstand vigorous mechanical shocks 
encounters in its production, packaging, shipping and dispensing.
 Should have chemical and physical stability.
On the other hand,
a. It must be able to release the medicinal agent in the body in a 
predictable and reproducible manner.
b. Must have a suitable chemical stability over time so as not to allow 
alterations of the medicinal agent.
c. Pre-compression of amorphous powders case negative effect on 
dissolution and disintegration rates.
2.7   Tabletting methods7
The three basic methods for the preparation of compressed tablets 
are
• Wet Granulation Method
• Dry Granulation Method or slugging method and
• Direct Compression
2.7.1   Direct compression
Direct compression consists of compressing tablets directly from 
powdered material without modifying the physical nature of the material 
itself. It involves only two operations, in sequence, powder mixing and 
tableting. The advantage of this is reduced cost production. The main 
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advantage of direct compression is it saves time when compared to other 
methods of compression like wet granulation.
Advantages of Direct Compression7
 The most obvious advantage is economy. Saving can occur in a 
number of areas including reducing process, time and thus reduced 
labour cost, fewer manufacturing steps and fewer equipments.
 Another advantage is in terms of tablet quality that is processing 
without the need of moisture and heat.
 Optimization of tablet disintegration in which each primary drug 
particle is liberated from tablet and available for dissolution.
 Fewer chemical stability problems would occur in direct 
compression.
 In direct compression, the disintegrant is able to perform optimally 
and when properly formulated, tablet made by direct compression 
should disintegrate rapidly to primary particles.
2.7.2   Requirements for directly compressible filler/binder are:
• High compactability to ensure that the compacted mass will remain 
bound after the release of the compaction pressure.
• Most directly compressible filler, binders undergo physical 
modification in order to improve tableting properties mainly 
compactability, flowabililty and apparent density.
• Good blending properties in order to avoid segregation.
• Most directly compressible materials are prepared by crystallization. 
The crystal size and in part the crystal shape are selected by sieving (or) 
in some cases after grinding. 
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2.7.3   Excipients used in direct compression:
 Fillers – Spray dried lactose, Microcrystalline cellulose (MCC), 
Dicalcium phosphate, micro crystals of alpha monohydrate lactose.
 Disintegrating agent – direct compression starch, sodium carboxy 
methyl starch, cross linked carboxy methyl cellulose fibres, cross 
linked polyvinyl pyrrolidone.
 Lubricants – magnesim stearate, talc.
 Glidants – fumed silicon dioxide.
2.7.4  Factors to be considered for directly compressible excipients:
Flow ability:
         Press speed requires powders to be very fluid, a property commonly 
referred to as product flow ability. Good flow characteristics are necessary 
because the mechanical action of the tablet press requires a volume of fill 
and this volume of fill represents the actual tablet weight. Thus the 
powders in the formula must possess a consistent particle-size distribution 
and density to attain proper flow and achieve volume of fill.
2.7.5   Compressibility:
Compressing a tablet of different powders that have varying 
physical characteristics can be difficult. If the formula has both 
characteristics like large particles with high moisture content and small dry 
particles then the tablet may or may not compress well and probably will 
have difficulty holding together.
Directly compressible materials are preprocessed or are found 
naturally in the granular state. The reduced number of processing steps 
required by directly compressible materials allows for less equipment and 
shorter process times in comparison with wet or dry granulation 
processes.
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2.8   A systemic and modern approach to tablet product design9
Tablet product design requires two major activities. First, 
formulation activities begin by identifying the excipients most suited for a 
prototype formulation of the drug. Second, the levels of those excipients in 
the prototype formula must be optimally selected to satisfy all 
process/product quality constraints.
Factors affecting the type of excipients used in a tablet formula
The type of excipients used may vary depending on a number of 
preformulation, medical, marketing, economic and process/product quality 
factors as discussed in the following sections. Here we mainly focus on the 
process/product quality.
2.9   Typical tests performed on tablets are as follows:
 Weight variation
 Hardness 
 Friability
 Disintegration time
 Dissolution
 Water content
 Content uniformity
Product quality is most often addressed at the tablet development 
stage. However, it is also important to monitor the processing quality of a 
formulation during development. They are:-
a. To optimize the process as well as the product.
b. To establish in-process quality control tests for routine 
production
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It is more difficult to quantify the processing quality of a formulation 
than it is to measure the product quality. Some measurements that could 
be preformed on the process include:-
 Ejection force
 Capping
 Sticking
 Take-off force
 Flow of lubricated mixture
 Press speed (maximum)
 Frequency of weight control adjustments
 Sensitivity of formula to different presses
 Tooling wear
 Effect of consolidation load (Batch size)
 Hopper angle for acceptable flow
 Hopper orifice diameter for acceptable flow
 Compressional forces
 Environmental conditions (temperature, humidity and dust)
Each of the above processing parameters can become a source of 
trouble in scale-up (or) routine production. By monitoring these parameters 
in development, it may be possible to adjust the formula (or) process early 
enough to alleviate the source of trouble. The expected production output 
(number of tablets) per unit time will determine what speed tablet press will 
be required for a particular tablet product. If the anticipated unit output for 
a tablet product is expected to be large, a high-speed press will be 
required.
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Attempts should be made in formulation development to design a 
tablet formula that will perform well on a high-speed press. A formula to 
run on a high-speed press should have excellent flow to maintain uniform 
die fill during compressing. It should have good bonding characteristics so 
that it can compress with a minimal dwell time.
2.10   Formulation of tablets and factors to be considered
The size and to some extent, the shape of the tablet are determined 
by the active ingredients. Drugs having very small doses in the microgram 
require the addition of fillers also called excipients to be added to produce 
a mass (or) volume of material that can be made into tablets of a size that 
is convenient for patients.
As the dose increases, so does the size of the table. Drugs with a 
dose of 100 to 200mg may require tablet weights of 150 to 300mg and 
round die diameters of 1/4 to 7/16 inches. The diameter depends on the 
density and compressibility of the powders used. As the dose of the active 
ingredient increases, the amount of the excipients and the size of the 
tablet may vary considerably depending on requirements of each to 
produce an acceptable tablet. While the diameter of the tablet may in 
some cases be fixed, the thickness is variable thus allowing the formulator 
considerable latitude and flexibility in adjusting formulations.
As the dose, and therefore the size of the tablet increases, the formulator 
uses his expertise and knowledge of excipients to keep the size of the 
tablet as small as possible without sacrificing its necessary attributes.
2.10.1 Formulation of a tablet requires the following considerations:
 Size of the dose (or) quantity of active ingredients 
 Stability of active ingredients.
 Solubility of active ingredients.
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 Density of active ingredients.
 Compressibility of active ingredients.
 Selection of excipients.
 Method of granulation (preparation for compression)
 Character of granulation
 Tablet press, type, size, capacity.
 Environmental conditions (ambient (or) humidity control)
 Stability of final product.
 Bioavailability of the active drug content of the tablet.
 The selection of excipients is critical in the formulation of tablets. 
Once the formulator has become familiar with the physical and 
chemical properties of the drug, the process of selecting excipients 
is begun. The stability of the drug should be determined with each 
proposed excipients. This can be accomplished as follows:
In the laboratory, prepare an intimate mixture of the drug with an 
excess of each individual excipients and hold at 60˚C for 72hrs in a 
glass container. At the end of this period analyze for the drug using 
a stability-indicating assay.
2.10.2   Different adjuvants used in tablet formulation
In addition to the active or therapeutic ingredient, tablets contain a 
number of inert materials called as additives or excipients. Excipients are 
specified according to the function they perform in the tablet. They are 
classified as follows
 Fillers (Diluents)
 Glidants
 Lubricants
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 Antiadherents, etc,
Diluents or Fillers7
These are the inert substances which will increase the bulk of 
tablet. Selecting the diluent is an important character while tabletting. 
These agents may not be necessary if the dose of drug per tablet is high. 
Generally, a tablet should weigh at least 100mg and therefore very low 
dose drugs will invariably require diluents to bring the overall tablet weight 
to atleast 100mg.
Diluents or fillers fall into two general categories:
1. Carbohydrate and modified carbohydrate excipients.
2. Inorganic materials
In wet granulation process, such carbohydrate substances as 
sugars, starches and cellulose may also function as binder. Where as in 
direct compression systems, they serve as diluent carrier. The inorganic 
excipients, when used in either system, are not binders that is a cohesive 
agent, in directly compressible system. Hence they function more as a 
carrier.
Microcrystalline cellulose:  (MCC) (AVICEL) is most widely used 
as direct compression tablet filler. It has a function of disintegrant besides 
that of a dry binder and is compatible with most excipients and active 
ingredients.
Lactose is an inexpensive, soluble and easily granulated diluent. 
Because it lacks flowability and compressibility in its common form. 
Lactose in modified form can only be used in direct compression.
The other commonly used diluents are mannitol, kaolin, dry starch, 
calcium sulfate, dicalcium phosphate.
Glidants1
Glidants improve the flow characteristics of the powder mixture. 
These materials are added in the dry state just prior to compression. They 
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act by reducing the inter-particulate friction and reduce the frictional forces 
between the granules and dies. Colloidal silicon dioxide is the most 
commonly used glidant and generally used in low concentration of 1% or 
less. Talc is also used and may serve the dual purpose of glidant/ 
lubricant. It is important to optimize the order of addition and mixing 
process of these materials to maximize their effect and to make sure that 
their influence on lubricants is minimized.
Lubricants
They have a number of functions in tablet manufacture:-
 They prevent adhesion of the tablet material to the surface of the 
dies and punches
 Reduce interparticle friction
 Facilitate the ejection of tablets from the die cavity
 Improves the rate of flow of tablet granulation
Commonly used lubricants include talc, magnesium stearate, 
calcium stearate, stearic acid, hydrogenated vegetable oils. Most 
lubricants are used in concentration below 1% when used alone. Talc is 
used in concentration as high as 5%. Lubricants are mostly hydrophobic 
materials. Poor selection or excessive amounts can result in water 
proofing the tablets, resulting in poor tablet disintegration and / or delayed 
dissolution of drug substance.
Antiadherents
These are useful in tablet formulation, which have a tendency to 
pick easily. Multivitamin products containing high vitamin E levels often 
display extensive picking which can be minimized through the use of 
colloidal silica such as syloid (0.1-0.5%)
2.11   Controlled release tablets11
Conventional drug therapy typically involves the periodic dosing of a 
therapeutic agent that has been formulated in a manner to ensure its 
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stability, activity and bioavailability. For most of the drugs, conventional 
methods of formulation are quite effective. However some drugs are 
unstable, toxic and have narrow therapeutic range, exhibit extreme 
solubility problems, require localization to a particular site in the body or 
require strict compliance or long term use. In such cases a method of 
continuous administration of drug is desirable to maintain fixed plasma 
drug levels. The goal in designing sustained or controlled delivery is to 
reduce the frequency of the dosing or to increase effectiveness of the drug 
by localization at the site of action, reducing the dose required or providing 
uniform drug delivery, so, controlled release dosage form is that release 
one or more drugs continuously in a predetermined pattern for a fixed 
period of time, either systemically or to a specified target organ. Controlled 
release dosage forms provide a better control of plasma drug levels, less 
dosage frequency, less side effect, increased efficacy and constant 
delivery.               
2.11.1   Potential advantages of controlled drug therapy:13
          All controlled release products share the common goal of improving 
drug therapy over achieved with their non-controlled counter parts. This 
improvement in drug therapy is represented by several potential 
advantages of the use of controlled release systems as mentioned below:
A) Avoid patient compliance problems.
B) Employ less total drug
• Minimize or eliminate local side effects.
• Minimize or eliminate systemic side effects.
• Obtain less potentiation or reduction in drug activity with chronic
use.
• Minimize drug accumulation with chronic dosing
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C) Improve efficiency in treatment
• Cure or control condition more promptly
• Improve control of condition i.e. reduce fluctuation in drug level.
• Improve bioavailability of some drugs.
• Make use of special effects e.g. sustained release aspirin for 
morning relief of arthritis by dosing before bedtime.
• Economy.
2.11.2   Limitations of oral CRDDS
On the other hand oral CRDDS suffer from a number of potential 
disadvantages:
 Relatively poor in vitro-in vivo correlation.
 Possible dose dumping
 Reduced potential for dose change or withdrawal in the event of 
toxicity
 Loss of effect due to diarrohea( too fast transit time)
2.12   Reasons for oral CRDDS
             There is a clinical need to develop the CR formulations to improve 
the drug therapy over that achieved with their conventional counterparts, 
especially in the following cases:
I) Short elimination half life (t ½) and minimum effective concentration 
(MEC) required for the therapy. Shorter the half life of a drug, larger 
will be the fluctuations between the maximum steady state 
concentration (CSS max) and the minimum steady state concentration 
( Css min) upon multiple dosing. If MEC is therapeutically required, 
either frequent dosing of a conventional drug product or 
development of a CR product is necessary.
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II) Similarly the drugs having reasonably long elimination half- life and 
either wide or narrow therapeutic range. May also need to be 
formulated as CR products mainly for:
o Two to three day extension and
o Minimize the fluctuations between CSS max and Css min with narrow 
therapeutic range drugs.
2.12.1   Drugs which are not ideal candidates for CR formulations
 Extensive first pass metabolism ( except prodrugs )
 Extremely short elimination half-life (low therapeutic index)
 Extremely long elimination half-life (narrow therapeutic 
range)
 Bioavailability problems
 Instability in GI environment
2.12.2   An ideal candidate for CRDDS
The desired biopharmaceutic characteristics of drugs to be used in 
the development of per oral CR dosage forms are:
• Molecular weight: < 1000 
• Solubility  : > 0.1 mcg/ml at PH 1 to 7.8
• Non ionized moiety : > 0.1% to 11%  at PH 1 to 7.8
• Apparent partition coefficient : 0.5 to 2.0
• General absorbability : from all GI segments
• Release should not be influenced by pH and enzymes
• Stability : stable in GI environment
• Less protein binding
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            To evaluate whether or not a drug is a viable candidate for the 
design of per oral CR formulations, one must consider the following 
pharmacokinetic parameters of the drug:
• Elimination half-life, t ½ : preferably between 0.5 to 8 hours
• Total clearance, CL : should not be dose dependant
• Elimination rate constant, Kel  : required for the design
• Apparent volume of distribution, Vd  the larger the Vd  and MEC , the 
larger will be the required dose size. The maximum dose to be 
incorporates into a peroral CR formulations is about 500 mg. the 
smaller the Vd the easier is incorporation of drug into dosage form.
• Absolute bioavailability, F: should be 75% or more.
• Absorption rate, ka : must be much greater than release rate
• Therapeutic concentration, Css av : the lower the Css av and the 
smaller the Vd, the lesser is the amount of drug required.
• Minimum toxic concentration, MTC: MTC and MEC, the further 
apart these two values are, the “safer” the dosage form and also 
suitable for drugs with very short half-life (t ½).  
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3. DRUG PROFILE
PROPRANOLOL HYDROCHLORIDE17,19
(β -adrenergic blocking agent)
Molecular Formula : C16H21NO2.HCl
Molecular weight : 295.8
Indication : Adrenergic  Non  Selective  β-receptor 
antagonist, which is used as Antihypertensive, 
Antianginal  and  Antiarrhythmic  drug  and  it  is 
used  in  the  management  of  Myocardial 
infarction and Pheochromocytoma.
Chemical Name     : (± )-1-Isopropylamino-3-(1-naphthyloxy)
                                       propan-2-ol hydrochloride. 
Composition14               : C (74.10%), N (5.40%), H (8.16%), O (12.34%)
Storage                      :  Store in a well-closed container.
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3.1 PHYSICAL AND CHEMICAL PROPERTIES19
Description : A  white  or  off-white  powder,  odourless 
crystalline powder, bitter in taste.
Solubility : Soluble  (1g  dissolves  in  10-30  ml)  in  water 
and  ethanol.  Slightly  soluble  in  chloroform, 
practically insoluble in ether.
Dissociation constant : pka = 9.05 
Partition coefficient : Log P (Octanol / water) = 2.75 – 2.65
pH : 5.0 – 6.0, determined in 1% w/v solution
Polymorphism : Propranolol  Hcl  is  known  to  have  two 
polymorphic forms.
Colour Tests : Mandelin’s Test-green; Marquis Test-green.
Infra-red spectrum : Principal peaks at wave numbers 1103, 1270, 
772,  1580,  795,  1240  (Propranolol 
hydrochloride, KBr disc).
3.2 PHARMACOLOGICAL ACTION18,21
3.2.1 Cardiovascular
Propranolol diminishes heart rate, force of contraction and cardiac 
output, having both negative ionotropic and chronotropic effects. Cardiac 
output, work and oxygen consumption are decreased by blockade of  β1 
receptors. These effects are useful in treatment of angina.
3.2.2 Peripheral vasoconstriction
Blockade of  β  receptors prevents  β2–mediated vasodialation. The 
reduction  in  cardiac  output  leads  to  decreased  blood  pressure.  This 
hypotension triggers a reflex peripheral vasoconstriction that is reflected in 
reduced blood flow to the periphery.
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3.2.3 Bronchoconstriction
Blocking  β2 receptors  in  lungs  of  susceptible  patient  causes 
contraction  of  the  bronchiolar  smooth  muscle.  This  can  precipitate  a 
respiratory crisis in patients with chronic obstructive pulmonary disease or 
asthma. β-blockers are thus contraindicated in patient with asthma.
3.2.4 Increased sodium retention
Reduced  blood  pressure  causes  a  decrease  in  renal  perfusion, 
resulting in an increase in Na+ retention and plasma volume.
3.2.5 Disturbance in glucose metabolism
β-blockade  leads  to  decreased  glycogenolysis  and  decreased 
glucagon secretion.
3.2.6 Blockade action of isoproterenol
Propranolol has the ability to block the actions of isoproterenol on 
cardiovascular system, so does not produce either the typical reduction in 
mean arterial pressure and diastolic pressure or cardiac stimulation. 
3.3 THERAPEUTIC EFFECTS21
• Hypertension:  Propranolol  lowers  blood  pressure  in  hypertension  by 
decreasing cardiac output.
• Glaucoma:  Propranolol  effectively  diminishes  intraocular  pressure in 
glaucoma by decreasing the secretion of aqueous humor by the ciliary 
body. 
• Migraine:  Propranolol  is  effective  in  treatment  of  chronic  migraine,  in 
which the drug decreases the incidence and severity of the attacks.
• Hyperthyroidism:  In  acute  hyperthyroidism (thyroid  storm),  β-blockers 
may be life saving in protecting against serious cardiac arrhythmias.
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• Angina Pectoris: Propranolol decreases the oxygen requirement of heart 
muscle and therefore is effective in reducing the chest pain on execution 
that is common in angina. Therefore propranolol is useful in the chronic 
management of stable angina, but not for acute treatment.
• Myocardial  infarction: Propranolol  has  a  protective  effect  on  the 
myocardium. It  also reduces the incidence of  sudden arrhythmic death 
after myocardial infarction.
3.4 ADVERSE EFFECTS21
• Bronchoconstriction:  An immediate contraction of  bronchiolar  smooth 
muscle prevents air from entering the lungs. Death by asphyxiation has 
been reported, so propranolol must never be used in chronic obstructive 
pulmonary disease.
• Arrhythmias:  Treatment with  β-blockers must never be stopped quickly 
because of the risk of precipitating cardiac arrhythmias.
• Sexual impairment: Because sexual function in the male occurs through 
α-adrenergic activation, β-blockers do not affect normal ejaculation or the 
internal  bladder  sphincter  function.  On  the  other  hand  some  men  do 
complain of impaired sexual activity.
• Disturbance  in  metabolism:  β-blockade  leads  to  decreased 
glycogenolysis and decreased glucagon secretion. Fasting hypoglycemia 
may occur.
• Drug interaction: Drug that interferes with the metabolism of propranolol 
such  as  cimetidine,  furosemide  and  chlorpromazine  may potentiate  its 
antihypertensive effects. Conversely that stimulate its metabolism, such 
as barbiturates, phenytoin and rifampacin, can mitigate its effects.
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3.5 TOXICITY
Toxic  effects  have  been  associated  with  plasma  concentration 
greater than 2 µg/ml and fatalities with concentration greater than 4µg/ml.
3.6 PHARMACOKINETIC PROPERTIES20
 Absorption
Propranolol is almost completely absorbed after oral administration 
(>90%) but undergoes extensive first-pass metabolism with considerable 
intersubject variation, bioavailability 10 to 50% (mean 30%). 
Peak  plasma  concentration  are  reached  with  in  1-2  hour  after  oral 
administration of a single dose.
 Distribution
Propranolol is rapidly distributed over tissues. It is highly lipophilic 
and moderately bound to plasma proteins (80 – 95%) mainly to  α-1 acid 
glycoprotein, volume of distribution (VOD) is about 4 liters/Kg. Propranolol 
is distributed into the lungs, liver, kidney, brain and heart.
 Metabolism & Excretion
 Propranolol is almost completely metabolized in the liver. The main 
metabolites  are  naphthoxyl  acetic  acid  (42%)  4-  hydroxy  Propranolol 
(41%)  and  Propranolol  o-glucuronide  (17%).  4-  hydroxy  Propranolol  is 
pharmacologically active and is equipotent to the parent drug. However 
due to rapid conjugation the contribution to the pharmacological effect is 
low.
Elimination half-life is about 4 hours 
Therapeutic concentration : In plasma, usually in the range 0.05 to 1µg/ml.
Clearance : Plasma clearance about 10 to 20 ml/min/kg.
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Dose : 30 to 40mg of Propranolol hydrochloride daily.
3.7 CONTRA INDICATION20
Sinus bradycardia, cardiogenic shock, pulmonary oedema, severe 
hyperactive  airway  disease.  compensated  cardiac  failure,  Raynaud’s 
disease, hypoglycemia, severe haemorrhage, 2nd or 3rd degree heart block.
3.8 INTERACTIONS
Decreased  effect  with  aluminium  and  calcium  salts,  NSAIDS, 
ampicillin, rifampicin. Concurrent use of chlorpromazine results in raised 
blood levels of additive hypotensive effect. Hypotensive effect reduced by 
indomethacin. Plasma levels may be increased by Hydralazine.
3.9 ADR15
Cold  extremities,  insomnia,  fatigue,  dizziness,  vivid  dreams, 
lassitude,  nausea,  constipation  (or)  diarrhea,  impotence,  wheezing, 
bronchospasm.
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4. POLYMER PROFILE22
4.1 ETHYL CELLULOSE 
Nonproprietary names 
BP : Ethylcellulose
PhEur : Ethylcellulosum
USPNF : Ethylcellulose
Synonyms: Aqua coat ECD; Aqualon; E462; Ethocel; Surelease.
Chemical name and CAS registry number
Cellulose ethyl ether [9004-57-3]
Empirical formula & molecular weight 
Ethylcellulose  with  complete  substitution  (DS=3)  is  C12H23O6 
(C12H22O5)n  C12H23O5 where  n  can  vary  to  provide  a  wide  variety  of 
molecular weights. Ethylcellulose, and ethyl ether of cellulose, is a long-
chain  polymer  of  β–anhydroglucose  units  jointed  together  by  acetal 
linkages.
Functional category
Coating  agent;  flavoring  fixative;  tablet  binder;  tablet  filler;  viscosity–
increasing agent.
4.1.1 Applications in pharmaceutical formulation or technology
Ethylcellulose  is  widely  used  in  oral  and  topical  pharmaceutical 
formulations; see Table 4.
The  main  use  of  ethylcellulose  in  oral  formulations  is  as  a 
hydrophobic  coating  agent  for  tablets  and  granules.  Ethylcellulose 
coatings are used to modify the release to a drug to mask an unpleasant 
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taste,  or  to  improve  the  stability  of  a  formulation;  for  example,  where 
granules  are  coated  with  ethylcellulose  to  inhibit  oxidation.  Modified  – 
release tablet formulations may also be produced using ethylcellulose as a 
matrix former.
Ethylcellulose, dissolved in an organic solvent or solvent mixture, 
can  be  used  on  its  own  to  produce  water  –  insoluble  films.  Higher  – 
viscosity ethylcellulose grades tend to produce stronger and more durable 
films. Ethylcellulose films may be modified to alter their solubility by the 
addition of hypromellose or a plasticizer. An aqueous polymer dispersion 
(or latex) of ethylcellulose such as Aquacoat ECD (FMC Biopolymer) or 
Surelease (Colorcon) may also be used to produce ethylcellulose films 
without the need for organic solvents.
Drug release through ethylcellulose coated dosage forms can be 
controlled by diffusion through the film coating. This can be a slow process 
unless  a  large  surface  area  (e.g.  pellets  or  granules  compared  with 
tablets) is utilized. In those instances, aqueous ethylcellulose dispersions 
are generally used to coat granules or pellets. Ethylcellulose-coated beads 
and granules have also demonstrated the ability to absorb pressure and 
hence protect the coating from fracture during compression. 
High-viscosity  grades  of  ethylcellulose  are  used  in  drug 
microencapsulation.  Release  of  a  drug  from  an  ethylcellulose 
microcapsule is a function of the microcapsule wall thickness and surface 
area. In tablet formulations, ethylcellulose may additionally be employed 
as a binder; the ethylcellulose may additionally be wet-granulated with a 
solvent such as ethanol (95%). Ethylcellulose produces hard tablets with 
low friability, although they may demonstrate poor dissolution.
Ethylcellulose  has  also  been  used  as  an  agent  for  delivering 
therapeutic  agents  from  oral  (e.g.,  dental)  appliances.  In  topical 
formulations,  Ethylcellulose  is  used  as  a  thickening  agent  in  creams, 
lotions, or gels, provided an appropriate solvent is used. Ethylcellulose is 
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additionally used in cosmetics and food products.
Table 4: Uses of Ethylcellulose
Use Concentration (%)
Microencapsulation 10.0-20.0
Sustained – release tablet coating 3.0-20.0
Tablet coating 1.0-3.0
Tablet granulation 1.0-30.0
Description
Ethylcellulose  is  a  tasteless,  free-  flowing,  white  or  light  tan-colored 
powder.
4.1.2 Typical properties 
Density (bulk) : 0.4g/cm 3 
Glass transition temperature : 129-133°C
Moisture content:
Ethylcellulose absorbs very little water from humid  air  or  during 
immersion, and that small amount evaporates 
Solubility:
Ethylcellulose  is  practically  insoluble  in  glycerin,  propylene  glycol,  and 
water.  Ethylcellulose that contains less than 46.5% of ethoxyl  groups is freely 
soluble  in  chloroform, methyl  acetate,  and tetrahydrofuran,  and in  mixtures of 
aromatic hydrocarbons with ethanol (95%). Ethylcellulose that contains not less 
than 46.5% of ethoxyl acetate, methanol and toluene.
Specific gravity: 1.12-1.15 g/cm3
Viscosity: The viscosity of ethylcellulose is measured typically at 25°C using 5% 
w/v  ethylcellulose  dissolved  in  a  solvent  blend  of  80% toluene:  20% ethanol 
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(w/w).  Grades  of  ethylcellulose  with  various  viscosities  are  commercially 
available;  see  Table  III.  They  may  be  used  to  produce  5% w/v  solutions  in 
organic solvent blends with viscosities normally ranging from 7 to 100 mPas (7-
100 cp).  Specific  ethylcellulose grades,  or  blends of  different  grades,  may be 
used to obtain solutions of a desired viscosity. Solutions of higher viscosity tend 
to be composed of longer polymer chains and produce strong and durable films.
4.1.3 Stability and storage conditions:
Ethylcellulose  is  a  stable,  slightly  hygroscopic  material.  It  is 
chemically resistant to alkalis,  both dilute and concentrated and to  salt 
solutions,  although  it  is  more  sensitive  to  acidic  materials  than  are 
cellulose esters.
Ethylcellulose  is  subject  to  oxidative  degradation  in  the  presence  of 
sunlight or UV light at elevated temperatures. This may be prevented by the use 
of antioxidant and chemical additives that absorb light in the 230-340 nm range. 
Ethylcellulose  should  be  stored  at  a  temperature  not  exceeding  32°C 
(90°F) in a dry area away from all sources of heat. It should not be stored next to 
peroxides or other oxidizing agents. 
Incompatibilities:
Incompatible with paraffin wax and microcrystalline wax.
4.1.4. Safety:
 Ethylcellulose is  widely  used in  oral  and topical  pharmaceutical 
formulations.  It  is  also  used  in  food  products.  Ethylcellulose  is  not 
metabolized  following  oral  consumption  and  is  therefore  a  noncalorific 
substance.  Because  ethycellulose  is  not  metabolized  it  is  not 
recommended for parenteral products; paranteral use may be harmful to 
the kidneys.
Ethylcellulose is generally regarded to be a health hazard; the WHO 
has not specified an acceptable daily intake.
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• LD50 (rabbit, skin): >5 g/kg (28)
• LD50 (rat,oral): >5 g/kg
Handling precautions:
It  is  important  to  prevent  fine  dust  clouds  of  ethylcellulose from 
reaching  potentially  explosive  levels  in  the  air.  Ethylcellulose  is 
combustible. Ethylcellulose powder may be an irritant to the eyes and eye 
protection should be worn.
4.2 XANTHAN GUM
Non proprietary names: 
• BP      :   Xanthan gum 
• PhEur  :  Xanthani gummi
• USPNF :  Xanthan gum
Synonyms: Corn  sugar  gum;  E415;  Keltrol;  polysaccharide  B-1459;     
Rhodigel; Vanzan NF; Xantural.
Chemical name and CAS Registry number
            Xanthan gum [11138-66-2]
Empirical formula:  
The  USPNF  20  describes  xanthan  gum  as  a  high  molecular  weight 
polysaccharide  gum.  It  contains  D-glucose  and  D-mannose  as  the  dominant 
hexose units, along with D-glucuronic acid.
The molecular weight is approximately 2×  106
Structural formula: 
Each xanthan gum repeat unit contains five sugar residues: two glucose, 
two mannose and one glucuronic acid. The polymer backbone consists of four β-
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D-glucose  units  linked  at  the  1  and  4  positions  and  is  therefore  identical  in 
structure  to  cellulose.  Each  side  chain  comprises  a  glucuronic  acid  residue 
between two mannose units. At most of the terminal mannose units is a pyruvate 
moiety; the resulting stiff polymer chain may exist in solution as a single, double, 
or triple helix that interacts with other xanthan gum molecules to form complex, 
loosely bound networks.
Functional category:
Stabilizing agent; suspending agent; viscosity-increasing agent.
4.2.1  Application in pharmaceutical formulation or technology22 
Xanthan gum is widely used in oral  and topical pharmaceutical 
formulations, cosmetics and foods as a suspending and stabilizing agent. 
It  is  also  used  as  a  thickening  and  emulsifying  agent.  It  is  nontoxic, 
compatible  with  most  other  pharmaceutical  ingredients  and  has  good 
stability and viscosity properties over a wide pH and temperature range.
           When xanthan gum is mixed with certain inorganic suspending  
agents,  such  as  magnesium  aluminum  silicate  or  organic  gums, 
synergistic rheological effects occur. In general mixtures of xanthan gum 
and magnesium aluminum silicate in ratios between 1:2 and 1:9 produce 
the optimum properties. Similarly, optimum synergistic effects are obtained 
with xanthan gum : guar gum ratios between 3:7 and 1:9.
           Although primarily used as a suspending agent, xanthan gum has 
also been used to prepare sustained-release matrix tablets.
           Xanthan gum is also used as a hydrocolloid in the food industry and  
in cosmetics it has been used as a thickening agent in shampoo.
Description:  Xanthan  gum  occurs as  a  cream  or  white  colored, 
odorless, free-flowing, fine powder.
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4.2.2  Typical properties
Acidity/alkalinity : pH = 6.0-8.0 for a 1% w/v aqueous solution.
Freezing point : 0°C for a 1% w/v aqueous solution.
Heat of combustion : 14.6 J/g (3.5cal/g)
Melting point : Chars at 270°C.
Particle size distribution:
various  grades  with  different  particle  sizes  are  available;  for  example, 
100% less than 180µm in size for Keltrol CG; 100% less than 75 µm in size for 
Keltrol  CGF;100%  less  than  250  µm,  95%  less  than  177  µm  in  size  for 
Rhodigel;100% less than 177 µm 92% less than 74 µm in size for Rhodigel 200.
Refractive index: : 1.333 for a 1% w/v aqueous solution. 
Solubility :  Practically insoluble in ethanol and ether; soluble in 
cold or warm water.
Specific gravity : 1.600 at 25°C
Viscosity (dynamic) : 200-1600  mPas  (1200-1600  cP)  for  a  1%  w/v 
aqueous solution at 25°C.
4.2.3  Stability and storage conditions 
Xanthan gum is  a  stable  material.  Aqueous solutions  are  stable 
over  a  wide  pH  range  of  3-12.  Although  they  demonstrate  maximum 
stability at pH 4-10 and temperatures of 10-60°C.  Xanthan gum solutions 
of less than 1% w/v concentration may be adversely affected by higher 
than ambient temperatures: for example, viscosity is reduced. Solutions 
are also stable in the presence of enzymes, salts, acids and bases.
The bulk material should be stored in a well-closed container in a 
cool, dry place.
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4.2.4  Incompatibilities
Xanthan gum is an anionic material and is not usually compatible 
with  cationic  surfactants,  polymers,  or  preservatives  as  precipitation 
occurs. Anionic and amphoteric surfactants at concentrations above 15% 
w/v cause precipitation of xanthan gum from a solution.
Xanthan  gum is  incompatible  with  oxidizing  agents,  some tablet 
film-coatings,  carboxymethylcellulose sodium, dried aluminum hydroxide 
gel,  and  some  active  ingredients  such  as  amitriptyline,  tamoxifen  and 
verapamil.
Method of manufacture
Xanthan  gum  is  a  polysaccharide  produced  by  a  pure-culture 
aerobic fermentation of a carbohydrate with Xanthomonas campestris. The 
polysaccharide is  then purified by recovery  with  propan-2-ol,  dried  and 
milled.
4.2.5  Safety
Xanthan  gum  is  widely  used  in  oral  and  topical  pharmaceutical 
formulations, cosmetics and food products and is generally regarded as 
non  toxic  and  nonirritant  at  the  levels  employed  as  a  pharmaceutical 
excipient.
The estimated acceptable daily intake for xanthan gum has been 
set by the WHO at upto 10 mg/kg body-weight.
Handling precautions
Observe normal precautions appropriate to the circumstances and 
quantity of material handled. Eye protection and gloves are recommended.
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Regulatory status
GRAS  listed accepted  for  use  as  a  food  additive  in  Europe. 
Included in the FDA inactive ingredients guide (oral solutions, suspensions 
and  tablets;  rectal  and  topical  preparations).  Included  in  nonparenteral 
medicines licensed in the UK.
4.3   GUAR GUM
Non proprietary names: 
BP :Guar galactomannan 
PhEur : Guar galactomannum
USPNF:Guar gum
Synonyms: E412;  Galactosol;  guar  flour;  jaguar  gum;  meprogat; 
meprodor; meyprofin; meyproguar.
Chemical name and CAS Registry number:
Galactomannan polysaccharide [9000-30-0]
Empirical formula:  (C6H12O6)n
Molecular weight : 220000
Structural formula: 
             Guar gum consists of linear chains of (1→4)-β-D-mannopyranosyl  
units  with  α-D-galactopyranosyl  units  attached  by  (1→6)  linkages.  The 
ratio of D-galactose to D-mannose is between 1:1.4 and 1:2
Functional category
Suspending  agent;  tablet  binder;  tablet  disintegrant;  viscosity-
increasing agent.
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4.3.1  Application in pharmaceutical formulation or technology22
           Guar gum is a galactomannan, commonly used in cosmetics, food  
products  and pharmaceutical formulations. It has also been investigated 
in  the  preparation  of  sustained-release  matrix  tablets  in  the  place  of 
cellulose derivatives such as methyl cellulose.
              In pharmaceuticals, guar gum is used in solid-dosage forms as a  
binder and disintegrant and in oral and topical products as a suspending, 
thickening and stabilizing agent and also as a controlled-release carrier. 
Guar gum has also been examined for use in colonic drug delivery.
           Therapeutically, guar gum has been used as part of the diet of  
patients  with  diabetes  mellitus.  It  has  also  been  used  as  an  appetite 
suppressant.
          
Table 5: Uses of guar gum
Use Concentration (%)
Emulsion stabilizer 1%
Tablet binder Up to 10%
Thickener for lotions and creams Up to 2.5%
4.3.2  Description 
The USPNF 20 describes guar gum as a gum obtained from the 
ground  endosperms  of  Cyamopsis  tetragonolobus  (L.)  Taub.  (fam. 
Leguminosae). It consists chiefly of a high-molecular weight hydrocolloidal 
polysaccharide,  composed  of  galactan  and  mannan  units  combined 
through  glycoside  linkages,  which  may  be  described  chemically  as  a 
galactomannan. 
           The main components are polysaccharides composed of D-
galactose and D-mannose in molecular ratios of 1:1.4 to 1:2. The molecule 
consists  of  a  linear  chain  of  β  -  (1→4)-  glycosidically  linked  manno-
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pyranoses and single α-(1→6)- glycosidically linked galacto-pyranoses.
           Guar gum occurs as an odorless, white to yellowish-white powder  
with a bland taste.
Typical properties
Acidity/alkalinity: pH = 5.0-7.0 (1% w/v aqueous dispersion)
Density : 1.492 g/cm3
Solubility: 
             Practically insoluble in organic solvents. In cold or hot water, guar  
gum disperses and swells almost immediately to form a   highly viscous, 
thixotropic sol. The optimum rate of hydration occurs at pH 7.5-9.0. Finely 
milled powders swell more rapidly and are more difficult to disperse. Two 
to  four  hours  in  water  at  room  temperature  are  required  to  develop 
maximum viscosity.
Viscosity (dynamic): 
4.86 Pas (4860cP) for a 1% w/v dispersion. Viscosity is dependent 
upon temperature, time, concentration, pH, rate of agitation and particle 
size of the guar gum. Synergistic rheological effects may occur with other 
suspending agents such as xanthan gum.
4.3.3  Stability and storage conditions 
           Aqueous guar gum dispersions have a buffering action and are 
stable between pH 4.0 and 10.5. however, prolonged heating reduces the 
viscosity of dispersions.
           The bacteriological stability of guar gum dispersions may be 
improved by the addition of a mixture of 0.15% methyl paraben and 0.02% 
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propyl paraben as a preservative. In food applications, benzoic acid, citric 
acid,  sodium benzoate or  sorbic acid  may be used.  Guar gum powder 
should be stored in a well-closed container in a cool, dry place.
Incompatibilities 
Guar gum is compatible with most other plant hydrocolloids such as 
tragacanth. It is incompatible with acetone, alcohol, tannins, strong acids 
and alkalis. Borate ions, if present in the dispersing water, will prevent the 
hydration of guar gum. However, the addition of borate ions to hydrated 
guar gum produces cohesive structural gels and further hydration is then 
prevented. The gel formed can be liquefied by reducing the pH to below 7 
or by heating. Guar gum may reduce the absorption of penicillin V from 
some formulations by a quarter.
4.3.4  Method of manufacture
Guar gum is obtained from the ground endosperm of the guar plant, 
Cyamopsis tetragonolobus (L.) Taub. (Fam. Leguminosae) which is grown 
in India, Pakistan and southwest region of the USA.
           The seed hull can be removed by grinding, after soaking in sulfuric 
acid or water or by charring. The embryo (germ) is removed by differential 
grinding,  since  each  component  possesses  a  different  hardness.  The 
separated endosperm, containing 80% galactomannan is then ground to 
different particle sizes depending upon final application.
Safety
         Guar  gum  is  widely  used  in  foods  and  oral  and  topical  
pharmaceutical  formulations.  Excessive  consumption  may  cause 
gastrointestinal  disturbance  such  as  flatulence,  diarrhea  or  nausea. 
Therapeutically,  daily  oral  doses of  up  to  25g of  guar  gum have been 
administered to patients with diabetes mellitus.
Although  it  is  generally  regarded  as  a  nontoxic  and  non-irritant 
material, the safety of guar gum when used as an appetite suppressant 
has been questioned. When consumed, the gum swells in the stomach to 
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promote  a  feeling  of  fullness.  However,  it  is  claimed  that  premature 
swelling  of  guar  gum  tablets  may  occur  and  cause  obstruction  of  or 
damage  to  the  oesophagus.  Consequently,  appetite  suppressants 
containing guar gum in tablet form have been banned in the UK. However, 
appetite suppressants containing microgranules of guar gum are claimed 
to be safe. The use of guar gum for pharmaceutical purposes is unaffected 
by the ban.
           In food applications, an acceptable daily intake of guar gum has not 
been specified by the WHO.
LD50 (rabbit, oral):7.0 g/kg
LD50 (rat,oral): 6.77 g/kg
4.3.5  Handling precautions
           Observe normal precautions appropriate to the circumstances and 
quantity of material handled. Guar gum may be irritating to the eyes. Eye 
protection, gloves and a dust mask or respirator are recommended.
Regulatory status 
            GRAS listed. Accepted for use as a food additive in Europe. 
Included in the FDA inactive ingredients guide (oral suspensions, syrups 
and tablets). Also included in nonparenteral medicines licensed in the UK.
Comments
              Synthetic derivatives of guar gum such as guar acetate, guar 
phthalate,  guar  acetate  phthalate,  oxidized  guar  gum  and  sodium 
carboxymethyl  guar  gum  have  also  been  investigated  for  their 
pharmaceutical applications. In particular sodium carboxymethyl guar gum 
gives a transparent gel and when poured over a pool of mercury, produces 
a  flexible,  clear,  transparent  film.  sodium carboxymethyl  guar  gum has 
been used as a polymer matrix in transdermal patches. 
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4.4  HYPROMELLOSE 
Nonproprietary names 
BP: Hypromellose 
JP: Hydroxypropylmethylcellulose 
PhEur: Hypromellosum
USP: Hypromellose
Synonyms 
          Benecel MHPC; hydroxypropyl methyl ether; E464; hydroxypropyl  
methylcellulose; HPMC; Methocel; methylcellulose propylene glycol ether; 
merthyl  hydroxypropylcellulose; Metolose ;  Pharmacoat ;  Spectracel  6 ; 
Spectracel 15; Tylopur.
Chemical name and CAS registry number 
Cellulose, 2-hydroxypropyl-methyl ether [9004-65-3]
Empirical formula molecular weight 
The PhEur 2002 describes hypromellose as a partly O-methylated 
and O-(2-hydroxypropylated)  cellulose.  It  is  available  in  several  grades 
that  vary  in  viscosity  and  extent  of  substitution.  Grades  may  be 
distinguished by appending a number indicative of the apparent viscosity,  
in mPa s, of a 2% w/w aqueous solution at 20°C. Hypromellose defined in 
the  USP  25  specifies  the  substitution  type  by  appending  a  four-digit  
number to the nonproprietary name: e.g., hypromellose 1828. The first two 
digits refer to the approximate percentage content of the methoxy group 
(OCH3).  The  second  two  digits  refer  to  the  approximate  percentage 
content of the methoxy group (OCH3). The second two digits refer to the 
approximate percentage content of the hydroxypropoxy group (OCH2CH 
(OH) CH3), calculated on a dried basis. Molecular weight is approximately 
10 000-1 500 000. The Jp 2001 includes three separate monographs for 
hypromellose:  hydroxypropylmethylcellulose  2208,  2906,  and  2910, 
respectively. 
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Functional category 
           Coating agent; film-former; rate – controlling polymer for sustained  
release;  stabilizing  agent;  suspending  agent;  tablet  binder;  viscosity  – 
increasing agent. 
4.4.1  Applications in pharmaceutical formulation or technology22 
           Hypromellose is widely used in oral and topical pharmaceutions,  
Particularly  ophthalmic  preparations.  Compared  with  methylcellulose, 
hypromellose produces solutions of greater clarity, with fewer undispersed 
fibers present,  and is therefore preferred in formulations for ophthalmic 
use.  Hypromellose  at  concentrations  between  0.45-1.0%  w/w  may  be 
added as a thickening agent to vehicles for eye drops and artificial tear 
solutions. 
           Hypromellose is also used as an emulsifier, suspending agent, and 
stabilizing agent in topical gels and ointments. As a protective colloid, it 
can prevent droplets and particles from coalescing or agglomerating, thus 
inhibiting the formation of sediments.       
 In addition, hypromellose is used in the manufacture of capsules, 
as  an  adhesive  in  plastic  bandages,  and  as  a  wetting  agent  for  hard 
contact lenses. It is also widely used in cosmetics and food products.
Description
           Hypromellose is an odorless and tasteless, white or creamy white 
fibrous or granular powder.
4.4.2  Typical properties
Acidity / alkalinity: pH = 5.5 – 8.0 for a 1% w/w aqueous solution
Ash: 1.5-3.0% depending upon the grade
Autoignition temperature: 360°C   
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Density (tapped): 0.557 g/cm3
Density (tapped): 1.326 g/cm3  
Melting point: browns at 190-200°C; chars at 225-230°C.
Glass transition temperature is 170-180°C.
Moisture content: 
            Hypromellose absorbs moisture from the atmosphere, the amount 
of water absorbed depending and relative humidity of the surrounding air. 
Solubility:
           Soluble  in  cold  water,  forming  a  viscous colloidal  solution; 
practically insoluble in chloroform, ethanol (95%), and ether, but soluble in 
mixtures  of  ethanol  and  dichloromethane,  mixtures  of  methanol  and 
dichloromethane,  and mixtures of  water  and alcohol.  Certain  grades of 
hypromellose  are  soluble  in  aqueous  acetone  solutions,  mixtures  of 
dichloromethane and propan-2-ol, and other organic solvents. 
Specific gravity: 1.26
4.4.3  Viscosity (dynamic):
            Wide ranges of  viscosity  types are commercially available. 
Aqueous solutions are most commonly prepared, although hypromellose 
may  also  be  dissolved  in  aqueous  alcohols  such  as  ethanol  and  
propan-2-ol  provided  the  alcohol  content  is  less  than  50%  w/w. 
Dichloromethane  and  ethanol  mixtures  may  also  be  used  to  prepare 
viscous hypromellose solutions. Solutions prepared using organic solvents 
tend to  be  more viscous;  increasing  concentration  also produces more 
viscous solutions.
51
HPMC grade Nominal Viscosity (mPa s)
K 100LVP 100 80-120
K4M 4000 3000-5600
K15M 15000 12000-21000
K100M 100 000 80 000-120 000
        
To  prepare  an  aqueous  solution,  it  is  recommended  that 
hypromellose is dispersed and thoroughly hydrated in about 20-30% of the 
required  amount  of  water.  The  water  should  be  vigorously  stirred  and 
heated to 80-90°C, then the remaining hypromellose added. Cold water 
should then be added to produce the required volume.
         When a water miscible organic solvent such as ethanol, glycol, or 
mixtures of ethanol and dichloromethane is used, the hypromellose should 
first be dispersed into the organic solvent, at a ratio of 5-8 parts of solvent 
to part of hypromellose. Cold water is then added to produce the required 
volume. 
4.4.4.  Stability and storage conditions
         Hypromellose powder is a stable material, although it is hygroscopic 
after  drying.  Solutions  are  stable  at  pH  3-11.  Increasing  temperature 
reduces the viscosity of solutions. Hypromellose undergoes a reversible 
sol-gel  transformation  upon  heating  and  cooling,  respectively.  The  gel 
point is 80-90°C, depending upon the grade and concentration of material.
Hypromellose powder  should be stored in a well-closed container,  in a 
cool, dry place.
Incompatibilities
          Hypromellose is incompatible with some oxidizing agents. Since it is 
nonionic,  hypromellose  will  not  complex  with  metallic  salts  or  ionic 
organics to form insoluble precipitates.
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Safety 
         Hypromellose is widely used as an excipient in oral and topical 
pharmaceutical formulations. It is also used extensively in cosmetics and 
food products. 
         Hypromellose is generally regarded as a nontoxic and nonirritant  
material, although excessive oral consumption may have a laxative effect. 
The WHO has not specified an acceptable daily intake fro hypromellose 
since the levels consumed were not considered to represent a hazard to 
health. 
LD 50 (mouse, IP): 5 g/kg (16)
LD 50 (rat, IP): 5.2 g/kg
Handling precautions 
         Observe normal precautions appropriate to the circumstances and 
quantity of material handled. Hypromellose dust may be irritant to the eyes 
and eye protection is recommended. Excessive dust generation should be 
avoided to minimize the risks of explosion. Hypromellose is combustible. 
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4.5    CELLULOSE, MICROCRYSTALLINE
Nonproprietary names
BP:         Microcrystalline cellulose
JP:          Microcrystalline cellulose
PhEur:    Cellulosum microcristallinum
USPNF: Microcrystalline cellulose
Synonyms
 Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline cellulose; E460; 
Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; Vivapur.
Chemical name and CAS Registry number
Cellulose [9004-34-6]
Empirical formula and molecular weight
(C6H10O5)n ≈36 000. where n ≈ 220.
Structural Formula
Functional Category
     Adsorbent; Suspending agent; Tablet and Capsule Diluent; Tablet Disintegrant.
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4.5.1   Applications  in  pharmaceutical  formulation  or  
technology22
         Microcrystalline  cellulose  is  widely  used  in  pharmaceuticals,  primarily  as  a 
binder/diluent  in  oral  tablet  and  capsule  formulations  where  it  is  used  in  both  wet-
granulation and direct-compression processes. In addition to its use as a binder/diluent, 
microcrystalline cellulose also has some lubricant and disintegrant properties that make it 
useful in tableting. Microcrystalline cellulose is also used in cosmetics and food products; 
see Table 6.
Table 6: Uses of microcrystalline cellulose
Use Concentration (%)
Adsorbent 20–90
Antiadherent 5–20
Capsule binder/diluent 20–90
Tablet disintegrant 5–15
Tablet binder/diluent 20–90
Description
Microcrystalline  cellulose  is  a  purified,  partially  depolymerized  cellulose  that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous particles. It  
is  commercially  available  in  different  particle  sizes  and  moisture  grades  that  have 
different properties and applications.
4.5.2  Typical properties
Solubility:  Slightly soluble in 5% w/v sodium hydroxide solution;  
practically  insoluble  in  water,  dilute  acids,  and  most  organic  
solvents.
Stability and storage conditions
Microcrystalline  cellulose  is  a  stable  though  hygroscopic  material.  The  bulk 
material should be stored in a well-closed container in a cool, dry place.
Incompatibilities
 Microcrystalline cellulose is incompatible with strong oxidizing agents.
4.5.3  Safety
        Microcrystalline cellulose is widely used in oral pharmaceutical formulations and 
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food products and is generally regarded as a relatively nontoxic and nonirritant material.  
Microcrystalline cellulose is not absorbed systemically following oral administration and 
thus has little toxic potential. Consumption of large quantities of cellulose may have a 
laxative effect, although this is unlikely to be a problem when cellulose is used as an 
excipient  in  pharmaceutical  formulations.  Deliberate  abuse  of  formulations  containing 
cellulose, either by inhalation or by injection, has resulted in the formation of cellulose 
granulomas.
Handling precautions
           Observe normal precautions appropriate to the circumstances and quantity of 
material  handled.  Microcrystalline  cellulose  may  be  irritant  to  the  eyes.  Gloves,  eye 
protection, and a dust mask are recommended. In the UK, the occupational exposure 
limits for cellulose have been set at 10 mg/m3 long-term (8-hour TWA) for total inhalable 
dust and 4 mg/m3 for respirable dust; the short-term limit for total inhalable dust has been 
set at 20 mg/m3.
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5. LITERATURE REVIEW
5.1 Veena  S  Belgamwar,  Madhura  V  Gaikwad,  et  al.,23 2009, 
Developed and evaluated Pulsatile drug delivery system designed 
for  chronopharmcotherapy  which  is  based  on  circadian  rhythm. 
Pulsatile drug delivery system is defined as the rapid and transient 
release  of  certain  amount  of  molecules  with  in  a  short  period 
immediately after a predetermined off-release period i.e. lag time. It 
consists of capsule or tablet composed of large number of pellets. 
Each pellets has a core that contain therapeutic drug and a water 
soluble osmotic agent (e.g., Nacl). The osmotic agent dissolves in 
water, which causes the pellets to swell & there by regulates the 
rate of diffusion of drug from the dosage form.
5.2 Usha Yogendra  Nayak,  Gopal  Venktesh Shavi,  et  al.,24 2009, 
developed  a   pulsatile  capsule  dosage  form  of  valsartan  for 
controlled  delivery.  In  the  majority  of  individuals  blood  pressure 
rises  in  the  early  morning  hours,  which  lead  to  serious 
cardiovascular  complications.  The  prepared  system  contained 
swellable  polymer  (L-hydroxypropyl  cellulose  (L-HPC),  xanthan 
gum,  polyethylene  oxide  or  sodium  alginate)  together  with  drug 
tablet  and  erodible  tablet  (L-HPC or  guar  gum)  in  a  pre-coated 
capsule. The formulation containing 200 mg sodium alginate and 
erodible tablet (150 mg) containing 50% guar gum and 46% lactose 
showed 5–6 h  lag  time and 10±2.1% drug release in  initial  6  h 
following  rapid  release  (99±1.7%  release  in  12  h)  of  drug  was 
observed. Thus this approach can provide a useful means for timed 
release of valsartan and may be helpful for patients with morning 
surge.
56
5.3 Yasser El-Malah, Sami Nazzal et al.,25 2008, studied on Novel use 
of Eudragit NE 30D/Eudragit L 30D-55 blends as functional coating 
materials in time-delayed drug release applications. It is formulated 
by Eudragit  NE 30D and L 30D-55 dispersions were  blended at 
50:50, 67:33, 75:25, and 80:20 ratios. Cast films were evaluated by 
texture  analysis  and  differential  scanning  colorimetry.  Increasing 
Eudragit NE 30D concentration increased miscibility, softness, and 
decreased stiffness of the films. At 80:20 ratio, the polymer blend 
was  completely  miscible  whereby  Eudragit  L  30D-55  was 
molecularly distributed in the mixture. This was confirmed by SEM 
analysis. A lag time could therefore be controlled by manipulating 
both the theoretical weight gain of the beads and the concentration 
of Eudragit NE 30D in the blend.
5.4 Qureshi.J,  Mohd,  Amir  Alka  Ahuja,  et  al.,26 2008, 
Chronomodulated drug delivery system of Salbutamol sulphate for 
the treatment of Nocturnal Asthma. It  consists of an effervescent 
core surrounded by consecutive layers of swelling and rupturable 
polymers.  The  core  containing  salbutamol  sulphate  &  different 
ratios of MCC & effervescent agent and then coated with an inner 
Swelling layer containing HPMC E5 and an outer rupturable layer 
having Eudragit RL/RS (1:1). The rupture & dissolution tests were 
studied  using  the  USP  paddle  method  at  50  rpm  in  0.1  N  Hcl 
&phosphate  buffer  pH  6.8.  The  lag  time  of  the  drug  release 
decreased by increasing the inner swelling layer and increased by 
increasing the rupturing layer level.
5.5 Ramón  C.  Hermida,  Diana  E.  Ayala,  et  al.,2 2007,  studied  on 
Chronotherapy of hypertension: valsartan administration at bedtime, 
as  opposed  to  upon  wakening,  results  in  an  improved 
diurnal/nocturnal  BP  ratio,  increased  percentage  of  controlled 
patients,  and significant  reduction in  urinary albumin excretion in 
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hypertensive  patients.  Chronotherapy  provides  a  new  option  to 
optimize BP control and to reduce the risk of cardiovascular disease 
(myocardial  infarction and stroke)  and of  end-organ injury of  the 
blood vessels and tissue of the heart, brain, kidney, eye, and other 
organs.
5.6 Michael  H.  Smolensky, Nicholas  A.  Peppas  et  al.,4 2007, 
investigated  on  Chronobiology,  drug-delivery  and 
chronotherapeutics.  chronotherapeutics  is  the  delivery  of 
medications  in the right concentration to the right targeted tissues 
at the right time to meet biological rhythm-determined needs, Many 
chronic  and acute medical  conditions exhibit  prominent  circadian 
patterns of symptom manifestation and severity. Among the many 
examples are allergic  rhinitis,  bronchial  asthma, and peptic  ulcer 
disease;  all  tend  to  worsen  overnight.  The  risk  of  many 
cardiovascular  events,  like angina pectoris,  myocardial  infarction, 
and thrombotic and hemorrhagic stroke, is greatest in the morning. 
The content of these articles clearly makes apparent many potential 
new applications of existing drug-delivery systems and devices, and 
it serves also as the basis for future developments.
5.7 Sarasija  Suresh,  H.N.  Shivakumar,  et  al.,27 2007,  studied  on 
Design  and  evaluation  of  pH  sensitive  minitablets  for 
chronotherapeutic delivery of Theophylline. The system comprising 
of Eudragit S-100 coated minitablets was designed for specifically 
target the nocturnal peak symptoms of asthma. The drug loaded 
core minitablets were produced by wet  granulation method using 
alcoholic solution of PVP K30 as a binder. Different coat weights of 
Eudragit S-100 were applied to the drug loaded core minitablets to 
produce  the  pH sensitive  minitablets.  In  vitro  dissolution  studies 
showed  that  a  coat  weight  of  10%  was  sufficient  for  effective 
release of the drug at higher pH values.
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5.8 Sarasija  Suresh,  H.N.  Shivakumar,  et  al.,28 2006,  studied  on 
design  and  evaluation  of  controlled  onset  extended  release 
multiparticulate  systems  for  chronotherapeutic  delivery  of 
Ketoprofen.  It  consists  of  drug-loaded  cellulose  acetate  cores 
encapsulated with in Eudragit S-100 microcapsules was designed 
for chronotherapeutic delivery of ketoprofen. Drug-loaded cellulose 
acetate  cores  were  prepared  by  emulsion  solvent  evaporation 
technique in an oily phase at different drug: polymer ratios (1:1, 2:1 
and  4:1).these  cores  were  successfully  microencapsulated  with 
Eudragit S-100 following the same technique at the core:coat ratio 
of 1:5. SEM revealed that the cellulose acetate cores were discrete, 
uniform& spherical. The aim was to minimize drug release in the 
upper part of the GI tract and target the drug to the colon.
5.9 Qureshi.J, Mohd, Sanjula Baboota, et al.,29 2006, investigated on 
Pulsatile  drug  delivery  system  having  a  peculiar  mechanism  of 
delivering the drug rapidly & completely after a “lag time”. i.e.,  a 
period  of  “no  drug  release”  though  most  delivery  systems  are 
designed for constant drug release over a prolonged period of time, 
constant blood levels of a drug may not always desirable. Pulsatile 
systems are designed in a manner that the drug is available at the 
site of action at the right time in the right amount.
5.10 D. Searle. LLC, et al.,30 2006, Covera-HS has a unique controlled-
onset   extended-release  (COER)  delivery  system,  which  is 
designed  for  bedtime  dosing,  results  in  a  maximum  plasma 
concentration (Cmax) of verapamil in the morning hours. Covera-HS 
was evaluated in  two placebo-controlled, parallel  design,  double-
blind studies of 382 patients with mild to moderate hypertension. In 
a clinical trial, 287 patients were randomized to placebo, 120 mg, 
180 mg, 360 mg, or 540 mg and treated for 8 weeks (the two higher 
doses were  titrated  from low doses and maintained for  6  and 4 
weeks, respectively). Covera-HS or placebo was given once daily at 
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10 pm and blood pressure changes were measured with 36-hour 
ambulatory blood pressure monitoring (ABPM). The results of these 
studies  demonstrate  that  Covera-HS,  at  180–540  mg,  is  a 
consistently and significantly more effective antihypertensive agent 
than placebo in reducing ambulatory blood pressures.
5.11 Sarasija Suresh, H.N. Shivakumar,  et al.,31 2006, studied on pH 
sensitive multi-particulate systems for chronotherapeutic delivery of 
Diltiazem  hydrochloride.  The  drug  loaded  core  pellets  were 
produced  by  aqueous  extrusion  spheronization  technique  using 
MCC as a spheronizing aid and PVP K30 as a binder. Different coat 
weights of several acrylic polymers were applied to the drug loaded 
pellets in an automatic coating machine. It was found that Eudragit  
S-100 shows a lag time of 5 hours at pH 7.0. The rapid drug release 
following an initial lag phase would ensure adequate protection in 
BP patients with early morning surge.
5.12 Shan-Yang Lin and Mei-Janeli et al.,33 2004,  Formulation Design 
of Double-layer in the Outer Shell of Dry-coated Tablet to Modulate 
Lag  Time  and  Time-controlled  Dissolution  Function:  Studies  on 
Micronized Ethyl  cellulose for Dosage Form Design It  consists of 
ethyl cellulose (EC) powder with a coarse particle (167.5μm) and 
several fine particles (<6 μm), respectively, were mixed toformulate 
the  whole  layer  of  the  outer  shell  of  dry-coated  tablets.  The 
formulations  containing  different  weight  ratios  of  coarse/fine 
particles of EC powders or 167.5 μm EC powder/excipient in the 
upper layer of the outer shell to influence the release behavior of 
sodium diclofenac from dry-coated tablet were also explored. The 
results  indicate that sodium diclofenac released from all  the dry-
coated tablets exhibited an initial lag period, followed by a stage of 
rapid drug release. When the mixture of the coarse/fine particles of 
EC powders was incorporated into the whole layer. 
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5.13 Yaw-Bin  Huang,  Yi-Hung  Tsai,  et  al.,34 2004, studied  on 
formulation design and in vitro/in vivo investigation of Once-daily 
propranolol extended-release tablet dosage form, it is composed of 
three formulation variables: the content of HPMC (X1); MCC (X2); 
and lactose (X3): The drug release percent at 1.5, 4, 8, 14 and 24 h 
were the target responses and were restricted to 15–30, 35–55,  
55–75, 75–90 and 90–110%, respectively. The results showed that 
the optimized formulation provided a dissolution pattern equivalent 
to the predicted curve, which indicated that the optimal formulation 
could  be  obtained  using  response  surface  methodology.  The 
mechanism of drug release from HMPC matrix tablets followed non-
Fickian  diffusion.  In  the  vivo  study,  the  MRT was  prolonged  for 
matrix tablets when compared with commercial immediate release 
tablets.
5.14 Mukai B., Utoguchi N  et al.,35 2002, prepared and evaluated the 
press-coated  Aminophylline  tablet  using  crystalline  cellulose  and 
PEG in the outer shell for timed-release dosage forms. The core 
tablet is prepared by direct compression method using rotary tablet 
punching  machine.  Press  coating  of  core  tablets  using  different 
ratios of crystalline cellulose and PEG. Tablets are evaluated for In-
vitro dissolution test showed a lag time of 6 hours.
5.15 Kung-Hsu Lin et al.,36 2001, studied the influence of compression 
force  to  inner  core  tablet  (or)  to  outer  coating  layer  of  the 
compression-coated  tablet on the  function  of  the  time controlled 
release.  Tabletting  was performed under  a compression force of 
1190–1530  kg/cm2 using  a  rotary  tabletting  machine 
(CLEANPRESS correct 12HUK kikusui Seisakusho, Kyoto, Japan). 
Concave punches 6 mm in diameter (curvature radius: 8 mm) were 
used  for  preparation  of  the  core  tablets.  Compression  of  core 
tablets  with  different  ratios  of  polymers  content  under  a 
compression force of 990-1140 kg/cm2.  It  was found that  perfect 
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drug  release  was  achieved  with  the  compression  force  of  
1120 kg/cm2.
5.16 Martti  Marvola et  al.,37 2001,  studied  the  development  and 
biopharmaceutical  evaluation  of  press-coated  tablets  with  the 
intention of administering formulation in the evening at 22:00, which 
provides  treatment  for  diseases  in  which  symptoms  are 
experienced  in  the  early  morning  hours  i.e. 
chronopharmacotherapy. The focus is to optimally deliver the drug 
in higher amounts in early morning hours (i.e. at time of greatest 
need) and lower amounts at night (i.e. when the need of drug is 
less).
5.17 Michael H. Smolensky and Erhard Haus et al.,1 2001, Circadian 
rhythms  and  clinical  medicine  with  applications  to  hypertension. 
illustrating the human circadian time structure is to depict the peak 
time of 24-h rhythms on a clock-like diagram and circadian rhythm 
of  diseases  and  chronotherapeutics.  It  is  found  that  Evening 
verapamil  chronotherapy  (Verelan  PM and  Covera-HS)  achieves 
more  complete  24-h  BP  control  than  once-a-day  conventional 
constant-release medications.
5.18 Madhusudan,  Hariharan et  al.,38 2001,  developed  a  novel 
compression  coated  tablet  dosage  form  which  describes  the 
dosage form not requires the separate formation of the core tablet 
because the core material and outer compression coating material 
are formed into a tablet in the same tablet press and on a single 
turret.
5.19 Michael Prisant .L  et al.3 2001, reported on Biologic rhythms are 
implicated  in  cardiovascular  events.  Failure  to  recognize  the 
circadian  decline  in  blood  pressure  may  result  in  iatrogenic 
chronopathological  events,  including  anterior  ischemic  optic 
neuropathy  and  cerebrovascular  accidents.  Novel  drug  delivery 
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systems have the potential to provide antihypertensive medication 
at  the  time  when  the  need  is  greatest.  For  the  treatment  of 
hypertension, this idea has the potential for a therapeutic paradigm 
shift Chronotherapeutics is the purposeful alteration of drug level to 
match rhythms to optimize therapeutic outcomes and minimize size 
effects for the treatment of hypertension.
5.20 Eiji Fukui*, Katsuji Uemura, et al.,39 2000, Studied on applicability 
of press-coated tablets using hydroxypropylcellulose (HPC) in the 
outer  shell  for  timed-release  preparations.  It  contains  diltiazem 
hydrochloride  (DIL)  in  the  core  tablet  and  coated  with 
hydroxypropylcellulose (HPC) as the outer shell, were examined for 
applicability as timed-release tablets with a predetermined lag time 
and subsequent rapid drug release phase. Two different kinds of 
timed-release press-coated tablets that showed lag times of 3 and 6 
h in the  in vitro test (denoted PCTL3 and PCTL6 respectively) were 
administered  to  beagle  dogs.  The  lag  times  showed  a  good 
agreement between the in vivo and in vitro tests in PCTL3. However, 
the  in  vivo lag  times  were  about  4  h  in  PCTL6 and  were  much 
shorter than the in vitro lag time.
5.21 White WB, Fakouhi T et al.,40 1998, studied Comparison of effects  
of  controlled  onset  extended  release  verapamil  at  bedtime  and  
nifedipine  (GITS). The  study  was  a  multicenter  (n  =  51),  
randomized, double-blind prospective clinical trial with a 10-
week  treatment  period.  Ambulatory  BP  monitoring  was 
performed at placebo baseline, after 4 weeks of stable double-
blind therapy, and at end of the study. Twenty-four-hour BP  
profiles were studied in 557 hypertensive patients. Changes in  
BP, HR, slope of the rate of rise of BP and HR, and the HR-
systolic BP product during the 4 hours from 1 hour before to 3  
hours  after  awakening  were  evaluated.  It  was  found  that  
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COER-verapamil  and  nifedipine  GITS  had  equivalent  effects  
(+/- 5/3 mm Hg) on early morning BP.
5.22 Richard J. Martin,MD, Monica Kraft, et al.,32 1995, investigated in 
Chronobiology and Chronotherapy in Respiratory medicine. It was 
found that, Chronotherapeutic delivery of theophylline, once daily in 
the  evening  between  6  p.m &  7  p.m controls  Asthma nocturnal 
symptoms and early morning bronchoconstriction. This regimen has 
been  found  to  be  clinically  superior  to  conventional  twice-daily 
dosing.
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6.  MATERIALS AND EQUIPMENTS
Table 7: Materials used
Material Grade Source
Propranolol Hcl IP Tristar formulation
Hydroxy propyl methyl cellulose K15M Sigma-aldrich
Microcrystaline cellulose DC Himedia Laboratories
Ethyl Cellulose 22 cp S.D fine chemicals
Xanthan gum - Himedia Laboratories
Guar gum M.W: 2,20,000 Himedia Laboratories
Magnesium stearate - S.D fine chemicals
Talc - S.D fine chemicals
Table 8 : Equipments used
Equipment Model / Company
Tablet punching machine Rimek Mini press
UV-visible spectrophotometer Jasco V-530
FT-IR spectrophotometer Jasco 410
Digital balance Denver instruments
Dissolution test apparatus Lab India disso 2000
Hardness tester Pfizer
Friabilator Camp-bell, India
Hot air oven Inlab equipments
Electronic vernier caliper Mitutoyo (India)
pH meter Metrohm, Switzerland
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7. PRE-FORMULATION STUDIES
Before  formulation  of  drug  substances  into  a  dosage  form,  it  is 
essential  that  it  should  be  chemically  and  physically  characterized. 
Preformulation studies give the information needed to define the nature of 
the drug substance and provide a framework for the drug combination with 
pharmaceutical excipients in the fabrication of a dosage form.
In  the  present  work,  preformulation  studies  on  the  purity, 
development  of  calibration  curve  of  the  drug  candidate  and  the 
compatibility between drug and excipients were carried out.
7.1 DEVELOPMENT  OF  CALIBRATION  CURVE  FOR  
PROPRANOLOL HYDROCHLORIDE
Spectral measurement
The standard solution of Propranolol Hcl was scanned between 400 
and 200 nm using UV-visible spectrophotometer.
7.1.1 Procedure for standard graph
 A  spectrophotometric  method  based  on  the  measurement  of 
absorbance at 290nm17 in phosphate buffer of pH 6.8 was used in the 
present  study  for  the  estimation  of  Propranolol  hydrochloride  (Indian 
pharmacoepia, 1996). 
An accurately weighed 100 mg of Propranolol  Hydrochloride was 
dissolved in phosphate buffer of pH 6.8 in a 100 ml volumetric flask and 
the solution was made up to the volume with phosphate buffer of pH 6.8 to 
give 1 mg/ml solution. From the above solution 10 ml was diluted to 100 ml 
using  phosphate  buffer  to  give  100µg/ml  working  stock  solution.  The 
above working  stock  solution  was  subsequently  diluted  with  phosphate 
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buffer of pH 6.8 to obtain a series of dilutions containing 10, 20, 30, 40 and 
50 µg/ml of solution. The λmax of the drug was determined by scanning the 
dilutions between 400 and 200 nm using a Shimadzu 1400 double beam 
UV-visible spectrophotometer. At this wavelength, the absorbances of all 
the other solutions are measured using the phosphate buffer of pH 6.8 as 
blank.  The  concentrations  of  Propranolol  hydrochloride  and  the 
corresponding  absorbance  values  are  given  in  table.  The  absorbance 
values were plotted against concentrations of Propranolol hydrochloride as 
shown in fig 5. The method obeys Beer-Lambert’s law in the concentration 
range of 10-50 µg/ml.
7.1.2 Preparation of pH 6.8 phosphate buffer 16
Place 50 ml of the 0.2 M potassium dihydrogen phosphate solution 
in a 200 ml standard volumetric flask and add 22.4 ml of 0.2M sodium 
hydroxide  solution  to  this  flask  and  make  up  the  volume with  distilled 
water.
 Potassium dihydrogen phosphate, 0.2 M solution
Take  accurately  weighed  27.22  gm  of  Potassium  dihydrogen 
phosphate and dissolved in 1000 ml of distilled water, this will give 0.2 M 
KH2PO4.
 Sodium hydroxide 0.2 M solution
Take accurately weighed 8 gm of sodium hydroxide and dissolved 
in 1000 ml of distilled water, this will give 0.2 M NaOH solution.
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Table 9: Standard graph of Propranolol hydrochloride in 
phosphate buffer pH 6.8
Sl. 
No.
Concentration (μg/ml) Absorbance at 290 nm
1 0 0.000
2 10 0.210
3 20 0.426
4 30 0.642
5 40 0.851
6 50 1.097
Fig 5: Standard graph of Propranolol hydrochloride in phosphate 
buffer pH 6.8
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7.2 COMPATIBILITY STUDIES
One of the requirements for the selection of suitable excipients or 
carrier for pharmaceutical formulation is its compatibility. Therefore in the 
present work, a study was carried out by using infrared spectrophotometer 
to  find  out  if  there  is  any  possible  interaction  between  the  drug  and 
excipients.
Weighed  amount  of  drug  (3mg)  was  mixed  with  100  mg  of 
potassium  bromide  (dried  at  40-50°C).  The  mixture  was  taken  and 
compressed  under  10-ton  pressure  in  a  hydraulic  press  to  form  a 
transparent  pellet.  The  pellet  was  scanned  from  4000-400  cm -1 in  IR 
spectrophotometer.
7.2.1 IR Spectral Analysis
Using FTIR spectrometer the compatibility studies between drugs 
and  the  carriers  was  carried  out.  There  was  no  appearance  or 
disappearance of any characteristic peak, which confirms the absence of 
chemical interaction between drug and carrier.
 Principal  peaks at  wave  numbers  1103,  1270,  772,  1580,  795, 
1240 (Propranolol hydrochloride, KBr disc).
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Fig 6: IR spectrum of propranolol Hcl
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Fig 7: IR spectrum of HPMC polymer
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Fig 8: IR spectrum of core tablet (Drug + HPMC)
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8. FORMULATION OF CONTROLLED ONSET 
EXTENDED RELEASE TABLETS 
The different  formulations  of  propranolol  hydrochloride  controlled 
onset  extended  release  tablets  were  formulated  by  press-coating 
technique  under  direct  compression  method  using  a  combination  of 
hydrophobic  polymer  ethylcellulose  and  natural  swellable  polymers 
xanthan gum and guar gum as outer coating layer.
8.1 FORMULATION OF CORE TABLETS
 The core tablets containing drug, HPMC and MCC, were prepared 
by weighing all the ingredients and passed through sieve no.80 and mixed 
in a geometrical dilution method. Magnesium stearate and talc (1% each) 
were added to each blend and further mixed. The resultant blends were 
tableted to 200 mg using concave punches in a rotary tabletting machine 
(Rimek minipress, India).
8.2 PRESS-COATING OF CORE TABLETS
The composition of the tablets is given in Table 10. Ethyl cellulose 
(EC)  and  each  mixture  of  xanthan  gum  and  guar  gum  were  passed 
through a sieve no.80 and 150 mg of the powder mixture was used for the 
outer shell. Different weight ratios of (w/w) of EC/excipient mixture were 
formulated  as  shown  in  Table  10.  The  press-coating  of  tablets  was 
performed using a rotary tabletting machine (Rimek minipress, India). A 
half amount of the EC/excipient mixture was filled into the die to make a 
powder bed, on the centre of which was placed the core tablet. Then, the 
remaining half  of the EC/excipient mixture was filled in the die and the 
contents were compressed to prepare the compression-coated tablet.
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Table 10: The composition and formulation code for various COER 
tablets containing propranolol Hcl
.
S. 
No.
Ingredients 
mg/tab
Formulation code
F1 F2 F3 F4 F5 F6 F7 F8 F9
1. Propranolol Hcl 100 100 100 100 100 100 80 120 100
2. HPMC 30 30 30 30 30 30 30 30 50
3.
Microcrystalline 
cellulose
q.s q.s q.s q.s q.s q.s q.s q.s q.s
4. Ethyl cellulose 75 100 50 75 100 50 75 75 75
5. Xanthan gum 75 50 100 - - - 75 75 75
6. Guar gum - - - 75 50 100 - - -
7.
Magnesium 
stearate
q.s q.s q.s q.s q.s q.s q.s q.s q.s
8. Talc q.s q.s q.s q.s q.s q.s q.s q.s q.s
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Table 11: The composition and formulation code of various PCT 
containing propranolol Hcl using EC & xanthan gum 
as outer coat.
S. NO. Formulation Code EC
Xanthan 
Gum IN RATIOS
1 F1 75mg 75 mg (1:1)
2 F2 100 mg 50 mg (2:1)
3 F3 50 mg 100 mg (1:2)
4 F7 75 mg 75 mg (1:1)
5 F8 75 mg 75 mg (1:1)
6 F9 75 mg 75 mg (1:1)
Table 12: The composition and formulation code of various PCT 
containing propranolol Hcl using EC & guar gum as outer coat.
S. NO Formulation 
Code
EC Guar 
gum
IN RATIOS
1 F4 75mg 75 mg (1:1)
2 F5 100 mg 50 mg (2:1)
3 F6 50 mg 100 mg (1:2)
The  hydrophilic  gums  are  extensively  used  for  oral  extended 
release  dosage  forms  due  to  their  simplicity,  cost  effectiveness  and 
reduction  of  the  risk  of  systemic  toxicity  due  to  dose  dumping. 
Furthermore, pH-independent drug release is preferable for oral extended 
release formulations, so as not to be affected by intra- and inter-subject 
variations  of  both  gastric  pH  and  GI  transit  time.  The 
hydroxypropylmethylcellulose (HPMC) is a pH-independent material  and 
the  drug  release  rates  from  HPMC  matrix  formulations  are  generally 
independent of processing variables such as compaction pressure, drug 
particle  size,  and the  incorporation  of  a  lubricant  .Therefore,  HPMC is 
widely used to prepare extended release dosage forms.
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9. EVALUATION OF TABLETS
The  formulated  tablets  were  subjected  for  the  following  quality 
control tests:
• Weight variation
• Hardness
• Friability
• Thickness
• Drug content uniformity
• Compatibility studies
• In vitro dissolution studies
9.1 WEIGHT VARIATION TEST
Ten  tablets  were  weighed  individually  as  per  USP.  They  were 
evaluated for the weight variations. The weight variation allowed as per 
USP limit is 5%. The weights of tablet were within the USP limits. The 
results are shown in Table no 14 & 15.
Table 13: Standard data of percentage deviation of tablets
 as per USP
Pharmaceutical 
form
Average mass % Deviation
Tablets
≤130 mg ± 10
> 130 mg - 324 mg ± 7.5
≥ 325 mg ± 5
Table 14: Weight variation of various PCT containing 
propranolol Hcl using EC/Xanthan gum as an outer coat
76
S. 
No.
Formulation 
code
Weight range of 
10 tablets in mg
Average 
weight in 
mg
Limit range 
(± 5%)
1 F1 345 – 358 351 333.5 - 368.5
2 F2 342 – 357 351 333.5 - 368.5
3 F3 346 – 357 350.5 332.9 - 368.1
4 F7 340 – 358 350.4 332.9 - 367.9
5 F8 345 - 360 351 333.5 - 368.5
6 F9 342 – 358 350.2 332.7 - 367.7
Table 15: Weight variation of various PCT containing 
propranolol Hcl using EC/ Guar gum as an outer coat
S. 
No.
Formulation 
code
Weight range of 
10 Tablets in mg
Average 
weight in 
mg
Limit range
(± 5%)
1 F4 345 – 356 350.4 332.9 - 367.9
2 F5 338 – 356 349.5 332.1 - 366.9
3 F6 342 – 357 350 332.5 - 367.5
9.2 FRIABILITY TEST
Friability test was performed on the formulated tablets using Roche 
friabilator  (Camp-bell  electronics,  India),  The weight  of  the tablets  after 
undergoing 100 revolutions was found to be within the limits 0.5 to 1.0%. 
The results are shown in Table 16 &17. 
9.3 HARDNESS
Pfizer  hardness  tester  was  used  for  measuring  the  hardness  of 
formulated propranolol TCR tablets. Five tablets were taken randomly and 
subjected to test. The hardness was found to be 4-6 kg/cm2. The results 
are shown in Table 16 & 17. 
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9.4 THICKNESS
Uniform  compression  force  and  volume  of  die  fill  leads  to  uniform 
thickness.  From each batch,  3  tablets  were  taken and checked with  a 
electronic thick-ness gauge (Mitutoyo, India) and the results are shown in 
Table 16.   
Table 16: Hardness, friability, thickness of various PCT containing 
propranolol Hcl using EC/Xanthan gum as an outer coat.
S. 
No.
Formulation 
code
Hardness 
(kg/cm2)
Friability
(%)
Average thickness 
in mm
1 F1 5.1 0.14 2.44
2 F2 5.2 0.19 2.61
3 F3 5.4 0.06 2.64
4 F7 5.0 0.14 3.16
5 F8 4.9 0.56 2.55
6 F9 5.7 0.06 2.71
Table 17: Hardness, friability, thickness of various PCT 
containing propranolol Hcl using EC/Guar gum as an outer coat.
S. 
No.
Formulation 
code
Hardness 
(kg/cm2)
Friability 
(%)
Average thickness 
in mm
1 F4 5.6 0.03 3.04
2 F5 5.3 0.11 2.92
3 F6 5.4 0.09 2.75
9.5 DRUG CONTENT UNIFORMITY16
The prepared tablets containing propranolol Hcl was tested for drug 
content uniformity. Transfer one tablet to a 100 ml volumetric flask which 
was previously clean and dry. 5 ml of dilute Hcl (1 in 100) was added and 
swirled occasionally until it is disintegrated, about 70 ml of methanol was 
added  and  sonicated  for  about  one  minute.  Diluted  with  methanol  to 
volume, mix and centrifuge a portion of the solution and measured the 
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absorbance of resulting solution at 290 nm in a Jasco V530 UV visible 
spectrophotometer. The results are shown in Table 18 & 19. 
Table 18: Drug content uniformity for various PCT containing 
propranolol Hcl using EC/xanthan gum as an outer coat 
S. No. Formulation code
Amount of propranolol per tablet
Amount in milligram % purity
1 F1 99.51 99.5 %
2 F2 99.25 99.3 %
3 F3 100.25 100.3 %
4 F7 79.60 99.5 %
5 F8 117.6 99.8 %
6 F9 100.75 100.8 %
Table 19: Drug content uniformity for various PCT containing 
propranolol Hcl using EC/guar gum as an outer coat
S. 
No. Formulation code
Amount of propranolol per Tablet
Amount in milligram  % purity
1 F4 101.0 101 %
2 F5 99.2 99.2 %
3 F6 99.0 99%
9.6  IN VITRO DISSOLUTION STUDIES34
 In vitro release of propranolol Hcl from nine different formulations 
were carried out by using dissolution paddle assembly (Lab india Disso 
2000) containing 900 ml of hydrochloric acid buffer (pH 1.2) for 2 hrs and 
900 ml of phosphate buffer (pH 6.8) for 22 hrs at 100 rpm and 37± 0.5°C. 
The 5 ml of samples were collected from each formulation in time interval 
of 1 hour till 8 hours and 12, 16, 20 and 24 th hours. Diluted suitably and 
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analysed  at  290  nm  in  UV  spectrophotometer,  from  the  results  the 
cumulative percentage drug release of propranolol Hcl from each press-
coated tablets were estimated using an equation obtained from standard 
curve (fig.5). The percentage release of propranolol Hcl from press-coated 
tablets are shown in the following Table 20.
Table  20:  Percentage  Invitro release  of  various  COER  tablets 
containing propranolol Hcl using various buffers.
Time 
(hrs)
Percentage release of propranolol Hcl from PCT
F1 F2 F3 F4 F5 F6 F7 F8 F9
0 0 0 0 0 0 0 0 0 0
1 0 0 0 0.2 0 1.5 0 0 0
2 0 0 0 2.3 0 5.3 0 0 0
3 0 0 2.3 7.4 0 8.2 0 0 0
4 4.2 0 6.1 11.5 0 18.4 3.6 4.5 3.3
5 11.6 0 12.6 23.7 0 29.5 9.8 8.2 6.4
6 21.2 12.5 24.5 36 14.5 42.4 21.2 24.1 19.5
7 34.6 23.6 36.2 55.6 29.4 49.2 30.8 32.6 26.9
8 43.8 38.5 46.5 74.3 39.6 68.6 40.2 42.7 34.8
12 70.4 68.1 72.9 82.3 69.5 86.1 71.2 73.4 62.1
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16 85.8 80.2 86.9 95.1 81.3 99.5 82.8 83.5 74.5
20 96.3 91.4 99.2 99.3 93.8 - 92.3 91.7 86.2
24 99.9 99.9 - - 99.4 - 99.8 99.6 92.7
Table 21: Dissolution profile of the chronotherapeutic formulation F1* 
containing propranolol Hcl using buffer pH 1.2 and 6.8 
Time 
(hr)
Absorbance
(290 nm)
Amount 
(µg/ml)
Amount 
(mg/900ml) Cumulative%release
1 0.000 0 0 0
2 0.000 0 0 0
3 0.000 0 0 0
4 0.0552 4.670 4.203 4.2
5 0.1510 12.84 11.556 11.6
6 0.2784 23.5 21.198 21.2
7 0.4544 38.44 34.600 34.6
8 0.5752 48.67 43.799 43.8
12 0.9245 78.22 70.396 70.4
16 1.1267 95.33 85.793 85.8
20 1.2646 107.0 96.300 96.3
24 1.3119 111.0 99.895 99.9
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Fig 9:  Percentage drug release of propranolol Hcl from COER tablets 
containing EC/Xanthan gum (1:1) as an outer coat using buffer 
pH 1.2 and 6.8
Table 22: Dissolution profile of the chronotherapeutic formulation F2* 
containing propranolol Hcl using buffer pH 1.2 and 6.8
Time (hr) Absorbance(290 nm) Amount (µg/ml)
Amount 
(mg/ 
900ml)
Cumulative
%release
1 0.000 0 0 0
2 0.000 0 0 0
3 0.000 0 0 0
4 0.000 0 0 0
5 0.000 0 0 0
6 0.1642 13.88 12.503 12.5
7 0.3099 26.22 23.599 23.6
8 0.5056 42.77 38.501 38.5
12 0.8944 75.67 68.107 68.1
16 1.0532 89.11 80.200 80.2
20 1.2003 101.56 91.403 91.4
24 1.3119 111.00 99.895 99.9
Fig 10:  Percentage drug release of propranolol Hcl from COER 
tablets containing EC/Xanthan gum (2:1) as an outer coat using 
buffer 
pH 1.2 and 6.8
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Table 23: Dissolution profile of the chronotherapeutic formulation F3* 
containing propranolol Hcl using buffer pH 1.2 and 6.8
Time 
(hr)
Absorbance
(290 nm)
Amount 
(µg/ml)
Amount 
(mg/900ml) Cumulative%release
1 0.000 0 0 0
2 0.000 0 0 0
3 0.0302 2.56 2.301 2.3
4 0.0801 6.78 6.102 6.1
5 0.1655 14.00 12.600 12.6
6 0.3217 27.22 24.501 24.5
7 0.4754 40.22 36.201 36.2
8 0.6106 51.67 46.502 46.5
12 0.9573 81.00 72.903 72.9
16 1.1412 96.55 86.903 86.9
20 1.3027 110.22 99.204 99.2
24 - - - -
Fig 11: Percentage drug release of propranolol Hcl from COER 
tablets containing EC/Xanthan gum (1:2) as an outer coat using 
buffer 
pH 1.2 and 6.8
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Table 24: Dissolution profile of the chronotherapeutic formulation F4* 
containing propranolol Hcl using buffer pH 1.2 and 6.8
Time 
(hr)
Absorbance
(290 nm)
Amount 
(µg/ml)
Amount 
(mg/900ml) Cumulative%release
1 0.0026 0.222 0.199 0.2
2 0.0302 2.56 2.300 2.3
3 0.0972 8.22 7.400 7.4
4 0.1510 12.78 11.501 11.5
5 0.3112 26.33 23.70 23.7
6 0.4727 40.0 36.001 36.0
7 0.7301 61.77 55.595 55.6
8 0.9757 82.55 74.303 74.3
12 1.0808 91.44 82.303 82.3
16 1.2489 105.66 95.104 95.1
20 1.3041 110.33 99.304 99.3
24 - - - -
Fig 12: Percentage drug release of propranolol Hcl from COER 
tablets containing EC/guar gum (1:1) as an outer coat using buffer 
pH 1.2 and 6.8
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Table 25: Dissolution profile of the chronotherapeutic formulation F5* 
containing propranolol Hcl using buffer pH 1.2 and 6.8
Time (hr) Absorbance
(290 nm)
Amount 
(µg/ml)
Amount 
(mg/900ml)
Cumulative
%release
1 0.000 0 0 0
2 0.000 0 0 0
3 0.000 0 0 0
4 0.000 0 0 0
5 0.000 0 0 0
6 0.1904 16.11 14.5 14.5
7 0.3861 32.66 29.401 29.4
8 0.5201 44.0 39.601 39.6
12 0.9127 77.22 69.502 69.5
16 1.0676 90.33 81.303 81.3
20 1.2318 104.22 93.804 93.8
24 1.3054 110.44 99.404 99.4
Fig 13: Percentage drug release of propranolol Hcl from COER 
tablets containing EC/guar gum (2:1) as an outer coat using buffer 
pH 1.2 and 6.8
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Table 26: Dissolution profile of the chronotherapeutic formulation F6* 
containing propranolol Hcl using buffer pH 1.2 and 6.8
Time 
(hr)
Absorbance
(290 nm)
Amount
 (µg/ml)
Amount 
(mg/900ml)
Cumulative
%release
1 0.0196 1.667 1.500 1.5
2 0.0696 5.88 5.299 5.3
3 0.1077 9.11 8.20 8.2
4 0.2416 20.44 18.40 18.4
5 0.3874 32.77 29.50 29.5
6 0.5568 47.11 42.401 42.4
7 0.6461 54.66 49.202 49.2
8 0.9009 76.22 68.602 68.6
12 1.1307 95.66 86.103 86.1
16 1.3067 110.55 99.504 99.5
20 - - - -
24 - - - -
Fig 14: Percentage drug release of propranolol Hcl from COER 
tablets containing EC/guar gum (1:2) as an outer coat using buffer 
pH 1.2 and 6.8
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Table 27: Dissolution profile of the chronotherapeutic formulation F7* 
containing propranolol Hcl using buffer pH 1.2 and 6.8
Time 
(hr)
Absorbance
(290 nm)
Amount 
(µg/ml)
Amount 
(mg/900ml)
Cumulative
%release
1 0.000 0 0 0
2 0.000 0 0 0
3 0.000 0 0 0
4 0.0378 3.20 2.880 3.6
5 0.1029 8.71 7.840 9.8
6 0.2227 18.84 16.960 21.2
7 0.3235 27.37 24.641 30.8
8 0.4223 35.73 32.161 40.2
12 0.7480 63.2 56.962 71.2
16 0.8699 73.6 66.242 82.8
20 0.9697 82.04 73.843 92.3
24 1.0485 88.71 79.843 99.8
Fig 15:   Percentage drug release of propranolol Hcl from COER 
tablets containing 80mg of drug and EC/Xanthan gum (1:1) as an 
outer coat using buffer pH 1.2 and 6.8
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Table 28: Dissolution profile of the chronotherapeutic formulation F8* 
containing propranolol Hcl using buffer pH 1.2 and 6.8
Time (hr) Absorbance(290 nm)
Amount 
(µg/ml)
Amount 
(mg/900ml)
Cumulative
%release
1 0.000 0 0 0
2 0.000 0 0 0
3 0.000 0 0 0
4 0.0709 6.00 5.400 4.5
5 0.1292 10.93 9.840 8.2
6 0.3797 32.13 28.921 24.1
7 0.5137 43.46 39.121 32.6
8 0.6729 56.93 51.242 42.7
12 1.1567 97.86 88.083 73.4
16 1.3158 111.3 100.204 83.5
20 1.4451 122.3 110.044 91.7
24 1.5696 132.8 119.525 99.6
Fig 16:   Percentage drug release of propranolol Hcl from COER 
tablets containing 120mg of drug and EC/Xanthan gum (1:1) as an 
outer coat using buffer pH 1.2 and 6.8
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Table 29: Dissolution profile of the chronotherapeutic formulation F9* 
containing propranolol Hcl using buffer pH 1.2 and 6.8
Time 
(hr)
Absorbance
(290 nm)
Amount
 (µg/ml)
Amount 
(mg/900ml)
Cumulative
%release
1 0.000 0 0 0
2 0.000 0 0 0
3 0.000 0 0 0
4 0.0433 3.66 3.300 3.3
5 0.0841 7.11 6.400 6.4
6 0.2561 21.66 19.501 19.5
7 0.3532 29.88 26.901 26.9
8 0.457 38.66 34.801 34.8
12 0.8155 69.0 62.102 62.1
16 0.9783 82.77 74.503 74.5
20 1.1321 95.77 86.203 86.2
24 1.2174 103.0 92.704 92.7
 
    
Fig 17:   Percentage drug release of propranolol Hcl from COER 
tablets containing 50mg of HPMC in core tablets and EC/Xanthan 
gum (1:1) as an outer coat using buffer pH 1.2 and 6.8
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Fig 18: The comparative dissolution profile of various 
formulations [F1 – F9] in pH 1.2 and 6.8 for 24 hrs.
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10. DRUG RELEASE KINETICS
Three categories of dissolution test specifications for drug products 
are  described  in  the  guidance.  Single  point  specifications  are 
recommended  as  a  routine  quality  control  test  for  highly  soluble  and 
rapidly  dissolving  drug  products.  This  comparison  method  can  be 
employed  in  evaluating  scale-up  and  post-approval  changes  such  as 
manufacturing  site  changes,  component  and  composition  changes, 
equipment  changes and process changes.  Two-point  specifications  are 
suggested for characterizing the quality of drug product and for accepting 
product  sameness  under  SUPAC-related  changes.  In  the  presence  of 
certain minor changes the single point dissolution test may be adequate to 
ensure  unchanged  product  quality  and  performance.  For  more  major 
changes  a  dissolution  profile  comparison  performed  under  identical 
conditions for the product before and after the changes is recommended. 
Dissolution profiles may be considered similar by virtue of overall profile 
similarity and similarity at every dissolution sample time point.
Method used to compare dissolution data is:
• Model  Dependent  Methods  (zero  order,  first  order,  Higuchi’s, 
Korsmeyer’s)
Drug Release Kinetics41
To  study  the  release  kinetics,  data  obtained  from  in  vitro  drug 
release  studies  were  plotted  in  various  kinetic  models:  zero  order 
(Equation 1) as cumulative amount of drug released vs. time, first order 
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(Equation 2) as log cumulative percentage of drug remaining vs. time, and 
Higuchi’s model (Equation 3) as cumulative percentage of drug released 
vs. square root of time.
C = K 0 t (Equation 1)
where K0 is the zero-order rate constant expressed in units of 
concentration/time and t is the time in hours.
A graph of concentration vs. time would yield a straight line with a 
slope equal to K0 and intercept the origin of the axes.
logc=logC0−kt /2 . 303 (Equation 2)
where C0 is the initial concentration of drug,
k is the first order constant, and t is the time.
Q = Kt
1
2 (Equation 3)
where K is the constant reflecting the design variables of the system
t is the time in hours.
Hence,  drug release rate  is  proportional  to  the  reciprocal  of  the 
square root of time.
Drug release were plotted in Korsmeyer et al., equation (Equation 
4) as log cumulative percentage of drug released vs. log time, and the 
exponent n was calculated through the slope of the straight line.
M t /M∞=Kt
n (Equation 4)
where Mt/M∞ is the fractional solute release, t is the release time,
K is a kinetic constant
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Table 30:  Drug release kinetics for various COER tablets containing 
propranolol HCl
Formulation Zero Order R2
First 
Order R2
Higuchi's 
Plot R2
Korsmeyer's 
Plot R2
F1 0.944 0.847 0.951 0.970
F2 0.938 0.948 0.923 0.983
F3 0.960 0.949 0.947 0.979
F4 0.889 0.944 0.923 0.945
F5 0.934 0.891 0.925 0.984
F6 0.966 0.817 0.962 0.966
F7 0.947 0.828 0.949 0.969
F8 0.938 0.866 0.946 0.956
F9 0.956 0.935 0.950 0.961
Fig 19: Drug release kinetics for F1 formulation
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Fig 20: Drug release kinetics for F2 formulation
Fig 21: Drug release kinetics for F3 formulation
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Fig 22: Drug release kinetics for F4 formulation
Fig 23: Drug release kinetics for F5 formulation
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Fig 24: Drug release kinetics for F6 formulation
Fig 25: Drug release kinetics for F7 formulation
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Fig 26: Drug release kinetics for F8 formulation
Fig 27: Drug release kinetics for F9 formulation
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11. RESULTS AND DISCUSSION
The aim of this work was to develop a chronotherapeutic delivery of 
propranolol Hcl in the form of press-coated tablets. Totally nine different 
press-coated tablets of propranolol Hcl were formulated by using various 
proportion of different polymers such as HPMC, ethyl cellulose, xanthan 
gum  and  guar  gum  by  direct  compression  method.  Here  we  selected 
propranolol Hcl as a drug candidate because of most commonly used in 
the  treatment  of  hypertension,  arrhythmia  and  angina  pectoris.  In  this 
study we develop a chronological dosage form to release the drug in the 
early morning between 3a.m to 6a.m because renin, cortisol, angiotensin, 
aldosterone  were  secreted  in  peak  level,  most  of  the  cardiovascular 
disorders such as angina pectoris, sudden cardiac death, stroke occurs in 
this time, the designed formulation was planned to taken at bedtime and 
the focus was to optimally deliver the drug in higher amounts in the early 
morning hours and lower amount at night.
The  prepared  press-coated  tablets  (F1  to  F9)  were  used  for 
evaluation of compatibility studies, physico-chemical parameters such as 
hardness, friability, thickness, weight variation, content uniformity,  in vitro 
release and in vitro release kinetics.
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11.1 COMPATIBILITY STUDIES
The  compatibility  studies  between  the  drugs  and  polymer  were 
evaluated by using IR matching approach.
FT-IR Spectral Analysis
In  IR  studies,  there  was  no  appearance  or  disappearance  of 
characteristics  peaks  in  pure  drug  and  drug  excipient  mixture.  In 
propranolol  Hcl  IR  spectrum,  principal  peaks  were  noticed  at  following 
wave numbers 1103, 1270, 772, 1580, 795, 1240cm -1 (KBr pellet). The IR 
spectra obtained are given in fig 6 to 8. This method confirms the absence 
of any chemical interaction between drug and polymer.
11.2 EVALUATION OF PROPRANOLOL HCL CONTROLLED ONSET 
EXTENDED RELEASE TABLETS
All  the  formulated  propranolol  controlled  onset  extended  release 
tablets (F1-F9) have fulfilled official requirements for weight variation and 
drug  content  uniformity  of  formulation  F4  and  F9  shows  maximum 
uniformity  around  101%  and  100.8%  respectively  (Table  18  and  19), 
hardness of the tablets in all the batches were found to be in the range of  
4.9 to 5.7 kg/cm2 (Table 16 and 17) and was satisfactory. The thickness of 
tablets  ranges  from  2.44mm  to  3.16mm  (Table  16  and  17)  and  the 
percentage weight loss in the friability test was found to be less than 1% in 
all formulations (Table 16 and 17) were found to be good quality fulfilling 
the tablets.
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11.3 IN VITRO DISSOLUTION STUDIES
In  vitro  drug  release  of  nine  different  press-coated  tablets 
containing  propranolol  Hcl  were  determined  by  using  USP  dissolution 
apparatus containing 900 ml of hydrochloric acid buffer (pH 1.2) for first 2 
hours and 900 ml of phosphate buffer (pH 6.8) for 22 hours at 100 rpm 
and 37 ± 0.5ºC. 5 ml of samples were taken, suitably diluted and analysed 
by  UV-spectrophotometer  at  290  nm.  From  the  results  the  cumulative 
percentage drug release were calculated for each tablet using an equation 
obtained from standard graph.
From the results of  in vitro  studies all  the prepared press-coated 
tablets (F1 to F9) were given a good release in the range of 92.7% w/v to 
99.9% w/v.  The formulation F2 [100mg of propranolol  Hcl,  EC:Xanthan 
gum (2:1)] and F5 [100mg of propranolol Hcl, EC:Guar gum (2:1)] were 
shown ideal release for chronotherpeutics. Because of having a lag time of 
5 hours and maximum release of 99.9 % w/v and 99.4 % w/v respectively.  
The in vitro dissolution data are given in Table 22 and 25 and the graphs 
are shown in fig 10 and 13.
The profiles clearly indicate that the propranolol Hcl released from 
the press-coated tablet exhibited a unique release profile depending on 
the amount of xanthan gum and EC used and also HPMC polymer in core 
tablet  contributes  in  drug  release  for  prolonged  period.  The  profile 
exhibited  an  induction  period  (lag  time)  followed  by  a  prolonged  drug 
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release throughout a day. The drug was released from the press-coated 
tablet after a lag period of 5-6 hours, depending upon the weight ratios of  
EC and  xanthan  gum.  The  swelling  of  the  outer  shell  of  press-coated 
tablets is a key factor to achieve the time-controlled delivery. The drug was 
released from the core tablet after rupturing, caused by the pressure build 
up  with  in  the  core  system.  Increasing  the  concentration  of  EC in  the 
formulation of the outer shell, the lag time was increased. The lag time 
changed according to weight ratios of the EC and xanthan gum as follows.
F3>F1>F2
The dissolution profile of EC/guar gum was also similar to that of 
the dissolution profile of EC/ xanthan gum, showing a distinctive inducting 
lag followed by drug release.  The lag time of  the press coated tablets 
containing  (1:1,  2:1  ,1:2)  ratios  of  EC/guar  gum  was  F6  >  F4  >  F5 
respectively.
It  is  evident  that  the time lag of  press-coated tablet  changes by 
varying the amount of EC and xanthan gum and guar gum in the outer 
shell. The dissolution profile of F7 & F8 formulation shows that the release 
rate  is  independent  of  the  drug  concentration.  Increase  in  amount  of 
HPMC  in  core  tablet  (formulation  F9)  increases  the  lag  time.  The 
dissolution profile of all the formulated propranolol time controlled release 
tablets were reported in Table 20.  
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11.4 DRUG RELEASE KINETICS
In vitro data obtained for propranolol Hcl controlled onset extended 
release tablets were used to determine the Drug release kinetics. The drug 
release  data  of  propranolol  Hcl  were  fitted  to  model  representing 
Korsmeyer’s equation (log cumulative percentage of drug released vs. log 
time) kinetics to know the release mechanisms. The data were processed 
for regression analysis using MS-EXCEL statistical functions (Table 30). In 
our study in vitro release profiles of drug from all the formulations could be 
best  expressed  by  Korsmeyer’s  equation  showed  highest  linearity  (R2 
0.984).  where  ‘n’  value  is  greater  than  0.89  so  it  follows  non-fickian 
diffusion. This explains why the drug diffuses at a comparatively slower  
rate.
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12. CONCLUSION
The main focus of chronotherapeutic formulation of propranolol Hcl 
is to optimally deliver the drug in higher amounts in early morning hours 
(i.e. at time of greatest need) and lower amounts at night (i.e. when the 
need of  drug is  less).  Because SBP and DBP rapidly  rise in  the early 
morning by at least 15 to 25 mm Hg and reach highest levels late in the 
day.  Typically  SBP  and  DBP  decline  in  sleep  by  10%  to  20%  from 
daytime.
From the results it was concluded formulation F2 (EC:xanthan gum, 
2:1) and F5 (EC:guar gum, 2:1) shows lag time of 5 hours consistent with 
requirement for chronotherapeutics and  the drug release was extended 
as shown in fig 22 and 25. The best lag time could be achieved by higher  
the  concentration  of  EC  in  outer  shell.  The  lag  time  could  also  be 
controlled by altering the weight ratios and viscosity grade of polymers.
• Hence COER Propranolol Hcl tablets can provide a useful means 
for timed release and may be helpful for BP patients with morning 
surge, which results in better compliance by patients and fewer side 
effects.
• In  conclusion,  the  time  lag  of  press-coated  tablet  could  be 
modulated by choosing the type and amount of excipient used in 
the  outer  shell  to  achieve  the  time-controlled  disintegration 
according to the time required The present study indicated that the 
lag time of the press-coated tablet can be suitably modulated by 
formulating the outer shell with ethyl cellulose and xanthan gum or 
guar gum.
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10 Tips to control Hypertension
1. Maintain a healthy weight.
2. Exercise each day (Be physically active).
3. Eat more fruits, vegetables and low-fat dairy foods.
4. Eat foods with less sodium (salt).
5. Limit alcohol consumption.
6. Reduce your stress and learn to relax.
7. Avoid tobacco products and secondhand smoke.
8. Cut back on caffeine.
9. Get regular healthcare.
10.Take prescribed drugs as directed.
